MCID: LNG032
MIFTS: 94

Lung Cancer malady

Genetic diseases (common), Respiratory diseases, Cancer diseases categories

Aliases & Classifications for Lung Cancer

About this section

Aliases & Descriptions for Lung Cancer:

Name: Lung Cancer 46 8 10 32 2
Non-Small Cell Lung Carcinoma 30 8 10 61
Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in 46 9
Nonsmall Cell Lung Cancer, Somatic 46 9
Carcinoma Non-Small Cell Lung 44 22
Nonsmall Cell Lung Cancer 46 9
Lung Carcinoma 8 44
Cancer of Lung 8 20
Cancer Lung 44 22
 
Nsclc 8 44
Nonsmall Cell Lung Cancer, Response to Tyrosine Kinase Inhibitor in 46
Adenocarcinoma of Lung, Somatic 46
Lung Cancer, Protection Against 46
Non-Small Cell Lung Cancer 8
Malignant Neoplasm of Lung 61
Lung Cancer, Somatic 46
Carcinoma of Lung 61


Classifications:



Summaries for Lung Cancer

About this section
MedlinePlus:32 Lung cancer is one of the most common cancers in the world. it is a leading cause of cancer death in men and women in the united states. cigarette smoking causes most lung cancers. the more cigarettes you smoke per day and the earlier you started smoking, the greater your risk of lung cancer. high levels of pollution, radiation and asbestos exposure may also increase risk. common symptoms of lung cancer include a cough that doesn't go away and gets worse over time constant chest pain coughing up blood shortness of breath, wheezing, or hoarseness repeated problems with pneumonia or bronchitis swelling of the neck and face loss of appetite or weight loss fatigue doctors diagnose lung cancer using a physical exam, imaging, and lab tests. treatment depends on the type, stage, and how advanced it is. treatments include surgery, chemotherapy, radiation therapy, and targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

MalaCards based summary: Lung Cancer, also known as non-small cell lung carcinoma, is related to adenocarcinoma and breast cancer, and has symptoms including autosomal recessive inheritanceand alveolar cell carcinoma. An important gene associated with Lung Cancer is EGFR (epidermal growth factor receptor), and among its related pathways are Pathways in cancer and Class I MHC mediated antigen processing and presentation. The drugs hydroxyurea and vinorelbine and the compounds serine and estrogen have been mentioned in the context of this disorder. Affiliated tissues include the lung, lung and skeletal muscle, and related mouse phenotypes are cellular and homeostasis/metabolism.

Disease Ontology:8 A respiratory system cancer that is located in the lung.

CDC:2 Lung cancer is the leading cause of cancer death and the second most common cancer among both men and women in the United States.

OMIM:46 Lung cancer is the leading cause of cancer deaths in the U.S. and worldwide. The 2 major forms of lung cancer are... (211980) more...

Wikipedia:64 Lung cancer, also known as carcinoma of the lung or pulmonary carcinoma, is a malignant lung tumor... more...

Related Diseases for Lung Cancer

About this section

Diseases in the Lung Cancer family:

Lung Carcinoma in Situ Lung Benign Neoplasm
Lung Cancer, Egfr-Related Lung Cancer, Gstm1-Related

Diseases related to Lung Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 498)
idRelated DiseaseScoreTop Affiliating Genes
1adenocarcinoma32.5EGFR, KRAS, ERBB2, GSTM1, CASP8, FASLG
2breast cancer32.1ERBB2, KRAS, EGFR, PIK3CA
3colorectal cancer31.8BRAF, KRAS, CASP8, FASLG, EGFR, PIK3CA
4retinoblastoma31.7IRF1, RASSF1, PIK3CA, ERBB2, EGFR, PARK2
5melanoma31.6KRAS, CASP8, FASLG, PPP2R1B, PIK3CA, BRAF
6leukemia31.6GSTM1, PARK2, IRF1, FASLG, CASP8, PIK3CA
7stomach cancer31.6ERBB2, EGFR, KRAS, RASSF1, CASP8, FASLG
8adenoma31.5BRAF, CYP2A6, RASSF1, KRAS, GSTM1
9hepatitis31.4CASP8, KRAS, FASLG, CYP2A6, IRF1
10small cell cancer of the lung, somatic31.4KRAS, PIK3CA, GSTM1, RASSF1, CASP8, EGFR
11glioblastoma31.4CASP8, EGFR, ERBB2, RASSF1, FASLG, IRF1
12esophageal cancer31.4EGFR, DLEC1
13adenomatous polyposis coli31.3BRAF, KRAS, RASSF1, IRF1
14nasopharyngeal carcinoma31.3RASSF1, EGFR, GSTM1, CYP2A6, PIK3CA
15lung cancer susceptibility 331.2PIK3CA, BRAF, PARK2, CASP8, RASSF1, ERBB2
16colon adenocarcinoma31.2KRAS, FASLG, CASP8
17myelodysplastic syndrome31.2KRAS, GSTM1, FASLG, IRF1
18thyroid cancer31.1BRAF, PIK3CA, RASSF1, GSTM1
19glioblastoma multiforme31.1CASP8, FASLG, PIK3CA, EGFR
20pancreatic cancer31.1KRAS, ERBB2, CASP8, BRAF, PIK3CA, EGFR
21acute leukemia31.0PIK3CA, GSTM1, KRAS, IRF1, CASP8
22prostate cancer31.0DLEC1, EGFR, ERBB2, CASP8, GSTM1
23malignant glioma31.0PIK3CA, FASLG, CASP8, EGFR
24large cell carcinoma30.9ERBB2, KRAS, EGFR
25seminoma30.9BRAF, KRAS, RASSF1
26hepatocellular carcinoma30.9CASP8, PIK3CA
27oral cancer30.9GSTM1, FASLG, EGFR
28transitional cell carcinoma30.8GSTM1, ERBB2, EGFR
29chronic lymphocytic leukemia30.8IRF1, FASLG, CASP8
30astrocytoma30.7PIK3CA, IRF1, FASLG, CASP8, EGFR, RASSF1
31endotheliitis11.0
32tongue squamous cell carcinoma10.9ERBB2, KRAS, EGFR, CASP8, RASSF1, GSTM1
33ovarian cancer, somatic10.9FASLG, IRF1, BRAF, PIK3CA, CASP8, RASSF1
34neuronitis10.9
35cervical cancer, somatic10.8EGFR, PIK3CA, RASSF1, GSTM1, CASP8, IRF1
36hypoxia10.8
37gastric adenocarcinoma10.8PIK3CA, KRAS, CASP8, GSTM1, ERBB2, FASLG
38cholangiocarcinoma10.8KRAS, PIK3CA, RASSF1, ERBB2, BRAF
39asbestosis10.8
40squamous cell carcinoma, head and neck10.8PIK3CA, GSTM1, RASSF1, EGFR
41lung benign neoplasm10.7RASSF1, CYP2A6, KRAS, EGFR
42silicosis10.7
43thyroid carcinoma, papillary10.7PIK3CA, RASSF1, BRAF
44brain cancer10.7PIK3CA, CASP8, FASLG, EGFR
45thyroid adenoma10.7RASSF1, BRAF, PIK3CA
46medulloblastoma10.7RASSF1, ERBB2, CASP8, PIK3CA
47hepatitis c10.7GSTM1, KRAS, CYP2A6, IRF1
48thyroid cancer, anaplastic10.7PIK3CA, BRAF, CASP8
49nicotine dependence, protection against10.7GSTM1, KRAS, CYP2A6
50factor vii deficiency10.7EGFR, ERBB2, KRAS

Graphical network of the top 20 diseases related to Lung Cancer:



Diseases related to lung cancer

Symptoms for Lung Cancer

About this section

Symptoms by clinical synopsis from OMIM:

211980

Clinical features from OMIM:

211980

HPO human phenotypes related to Lung Cancer:

id Description Frequency HPO Source Accession
1 autosomal recessive inheritance HP:0000007
2 alveolar cell carcinoma HP:0006519

Drugs & Therapeutics for Lung Cancer

About this section

FDA approved drugs:

(show all 18)
id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Abraxane13 38 PACLITAXEL Celgene; Approved October 2012;
FDA Label: Abraxane
Malady that Drug Treats: non-small cell lung cancer;
Indications and Usage:13 ABRAXANE is a microtubule inhibitor indicated for the treatment of:; Metastatic breast cancer, after failure of combination chemotherapy; for metastatic disease or relapse within 6 months of adjuvant; chemotherapy. Prior therapy should have included an anthracycline; unless clinically contraindicated. (1.1); Locally advanced or metastatic non-small cell lung cancer (NSCLC),; as first-line treatment in combination with carboplatin, in patients who; are not candidates for curative surgery or radiation therapy. (1.2); Metastatic adenocarcinoma of the pancreas as first-line treatment, in; combination with gemcitabine. (1.3)
DrugBank Targets:11 1. Apoptosis regulator Bcl-2; 2. Tubulin beta-1 chain;; 3. Nuclear receptor subfamily 1 group I member 2; 4. Microtubule-associated protein 4; 5. Microtubule-associated protein 2; 6. Microtubule-associated protein tau
Mechanism of Action:13 
Target: microtubule
Action: inhibitor
FDA: ABRAXANE is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules; by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule; network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or  bundles of; microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.
2
Alimta13 38 PEMETREXED (also Pemetrexed Disodium) Eli Lilly Approved February 2004
FDA Label: Alimta
Malady that Drug Treats: Mesothelioma
Indications and Usage:13 ALIMTA®; is a folate analog metabolic inhibitor indicated for:; Locally Advanced or Metastatic Nonsquamous Non-Small Cell; Lung Cancer:; Initial treatment in combination with cisplatin. (1.1); Maintenance treatment of patients whose disease has not; progressed after four cycles of platinum-based first-line; chemotherapy. (1.2); After prior chemotherapy as a single-agent. (1.3); Mesothelioma: in combination with cisplatin. (1.4); Limitations of Use:; ALIMTA is not indicated for the treatment of patients with; squamous cell non-small cell lung cancer. (1.5)
DrugBank Targets:11 1. Thymidylate synthase; 2. Bifunctional purine biosynthesis protein PURH; 3. Dihydrofolate reductase; 4. Trifunctional purine biosynthetic protein adenosine-3
Mechanism of Action:13 
Target: folic acid/ thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase
Action: antagonist/ inhibitor
FDA: ALIMTA, pemetrexed for injection, is a folate analog metabolic inhibitor that exerts its action by disrupting folatedependent; metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits; thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT),; which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides.; Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding; protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme; folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT.; Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, is thought to occur to a; lesser extent, in normal tissues. Polyglutamated metabolites are thought to have an increased intracellular half-life; resulting in prolonged drug action in malignant cells.
3
Avastin13 38 BEVACIZUMAB Genentech Approved July 2009
FDA Label: Avastin
Malady that Drug Treats: renal cell carcinoma & Colorectal Cancer
Indications and Usage:13 Avastin is a vascular endothelial growth factor-specific angiogenesis; inhibitor indicated for the treatment of:; Metastatic colorectal cancer, with intravenous 5-fluorouracil-based; chemotherapy for first- or second-line treatment. (1.1); Metastatic colorectal cancer, with fluoropyrimidine- irinotecan- or; fluoropyrimidine-oxaliplatin-based chemotherapy for second-line; treatment in patients who have progressed on a first-line Avastincontaining; regimen. (1.1); Non-squamous non-small cell lung cancer, with carboplatin and paclitaxel; for first line treatment of unresectable, locally advanced, recurrent or; metastatic disease. (1.2); Glioblastoma, as a single agent for adult patients with progressive disease; following prior therapy. (1.3); -Effectiveness based on improvement in objective response rate. No data; available demonstrating improvement in disease-related symptoms or; survival with Avastin.; Metastatic renal cell carcinoma with interferon alfa (1.4); Cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel; and topotecan in persistent, recurrent, or metastatic disease. (1.5); Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary; peritoneal cancer, in combination with paclitaxel, pegylated liposomal; doxorubicin or topotecan (1.6) Limitation of Use: Avastin is not indicated for adjuvant treatment of colon; cancer. (1.1)
DrugBank Targets:11 1. Vascular endothelial growth factor A; 2. Low affinity immunoglobulin gamma Fc region receptor III-B; 3. Complement C1r subcomponent; 4. Complement C1q subcomponent subunit A; 5. Complement C1q subcomponent subunit B; 6. Complement C1q subcomponent subunit C; 7. Low affinity immunoglobulin gamma Fc region receptor III-A; 8. High affinity immunoglobulin gamma Fc receptor I; 9. Low affinity immunoglobulin gamma Fc region receptor II-a; 10. Low affinity immunoglobulin gamma Fc region receptor II-b; 11. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:13 
Target: VEGF
Action: inhibitor
FDA: Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR); 697 on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial; 698 cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration; 699 of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction; 700 of microvascular growth and inhibition of metastatic disease progression
4
Cyramza13 38 RAMUCIRUMAB Eli Lilly Approved April 2014
FDA Label: Cyramza
Malady that Drug Treats: gastric cancer
Indications and Usage:13 CYRAMZA® is a human vascular endothelial growth factor receptor 2; antagonist indicated; as a single agent or in combination with paclitaxel, for treatment; of advanced gastric or gastro-esophageal junction; adenocarcinoma, with disease progression on or after prior; fluoropyrimidine- or platinum-containing chemotherapy. (1.1); in combination with docetaxel, for treatment of metastatic nonsmall; cell lung cancer with disease progression on or after; platinum-based chemotherapy. Patients with EGFR or ALK; genomic tumor aberrations should have disease progression on; FDA-approved therapy for these aberrations prior to receiving; CYRAMZA. (1.2); in combination with FOLFIRI, for the treatment of metastatic; colorectal cancer with disease progression on or after prior; therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.; (1.3)
DrugBank Targets: -
Mechanism of Action:13 
Target: ligand-stimulated activation of VEGF Receptor 2
Action: inhibitor
FDA: Ramucirumab is a vascular endothelial growth factor receptor 2 antagonist that specifically binds VEGF Receptor; 2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligandstimulated; activation of VEGF Receptor 2, thereby inhibiting ligand-induced proliferation, and migration of human; endothelial cells. Ramucirumab inhibited angiogenesis in an in vivo animal model.
5
Gemzar13 38 GEMCITABINE HYDROCHLORIDE Eli Lilly Approved May 1996
FDA Label: Gemzar
Malady that Drug Treats: pancreatic cancer/Lung cancer
Indications and Usage:13 Gemzar® is a nucleoside metabolic inhibitor indicated:; in combination with carboplatin, for the treatment of advanced ovarian; cancer that has relapsed at least 6 months after completion of platinumbased; therapy (1.1); in combination with paclitaxel, for first-line treatment of metastatic; breast cancer after failure of prior anthracycline-containing adjuvant; chemotherapy, unless anthracyclines were clinically contraindicated; (1.2); in combination with cisplatin for the treatment of non-small cell lung; cancer (1.3); as a single agent for the treatment of pancreatic cancer (1.4)
DrugBank Targets:11 1. DNA; 2. Ribonucleoside-diphosphate reductase large subunit; 3. Thymidylate synthase; 4. UMP-CMP kinase
Mechanism of Action:13 
Target: ribonucleotide reductase
Action: inhibitor
FDA: Gemcitabine kills cells undergoing DNA synthesis and blocks the progression of cells through the G1/S-phase boundary.; Gemcitabine is metabolized by nucleoside kinases to diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. Gemcitabine; diphosphate inhibits ribonucleotide reductase, an enzyme responsible for catalyzing the reactions that generate deoxynucleoside; triphosphates for DNA synthesis, resulting in reductions in deoxynucleotide concentrations, including dCTP. Gemcitabine; triphosphate competes with dCTP for incorporation into DNA. The reduction in the intracellular concentration of dCTP by the action; of the diphosphate enhances the incorporation of gemcitabine triphosphate into DNA (self-potentiation). After the gemcitabine; nucleotide is incorporated into DNA, only one additional nucleotide is added to the growing DNA strands, which eventually results in; the initiation of apoptotic cell death.
6
Gilotrif13 38 AFATINIB DIMALEATE Boehringer Ingelheim Approved July 2013
FDA Label: Gilotrif
Malady that Drug Treats: metastatic non-small cell lung cancer with EGFR mutations
Indications and Usage:13 GILOTRIF is a kinase inhibitor indicated for the first-line treatment of; patients with metastatic non-small cell lung cancer (NSCLC) whose tumors; have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21; (L858R) substitution mutations as detected by an FDA-approved test (1); Limitation of Use: Safety and efficacy of GILOTRIF have not been; established in patients whose tumors have other EGFR mutations (1)
DrugBank Targets:11 1. Epidermal growth factor receptor; 2. Receptor tyrosine-protein kinase erbB-2; 3. Receptor tyrosine-protein kinase erbB-4
Mechanism of Action:13 
Target: tyrosine kinase autophosphorylation
Action: inhibitor
FDA: Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and; irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling.; Afatinib demonstrated inhibition of autophosphorylation and in vitro proliferation of cell lines expressing wildtype; EGFR or those expressing selected EGFR exon 19 deletion mutations or exon 21 L858R mutations,; including some with a secondary T790M mutation, at afatinib concentrations achieved, at least transiently, in; patients. In addition, afatinib inhibited in vitro proliferation of cell lines overexpressing HER2.; Treatment with afatinib resulted in inhibition of tumor growth in nude mice implanted with tumors either; overexpressing wild type EGFR or HER2 or in an EGFR L858R/T790M double mutant model.
7
Hycamtin13 38 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham Approved October 2007/Approved May 1996
FDA Label: Hycamtin
Malady that Drug Treats: small cell lung cancer/ ovarian cancer
Indications and Usage:13 HYCAMTIN for injection is a topoisomerase inhibitor indicated for:; metastatic carcinoma of the ovary after disease progression on or after; initial or subsequent chemotherapy. (1.1); small cell lung cancer platinum-sensitive disease in patients who; progressed after first-line chemotherapy. (1.2); combination therapy with cisplatin for Stage IV-B, recurrent, or; persistent carcinoma of the cervix which is not amenable to curative; treatment. (1.3)
DrugBank Targets:11 1. DNA topoisomerase 1; 2. DNA topoisomerase I, mitochondrial; 3. DNA
Mechanism of Action:13 
Target: topoisomerase I
Action: inhibitor
FDA: Topoisomerase I relieves torsional strain in DNA by inducing reversible single-strand breaks.; Topotecan binds to the topoisomerase I-DNA complex and prevents re-ligation of these singlestrand; breaks. The cytotoxicity of topotecan is thought to be due to double-strand DNA damage; produced during DNA synthesis, when replication enzymes interact with the ternary complex; formed by topotecan, topoisomerase I, and DNA. Mammalian cells cannot efficiently repair; these double-strand breaks.
8
Iressa13 38 GEFITINIB AstraZeneca Approved May 2003
FDA Label: Iressa
Malady that Drug Treats: Non-Small-Cell Lung Cancer
Indications and Usage:13 IRESSA is indicated as monotherapy for the continued treatment of patients with locally advanced or; metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel; chemotherapies who are benefiting or have benefited from IRESSA.; In light of positive survival data with other agents including another oral EGFR inhibitor, physicians; should use other treatment options in advanced non-small cell lung cancer patient populations who; have received one or two prior chemotherapy regimens and are refractory or intolerant to their most; recent regimen. The effectiveness of IRESSA was initially based on objective response rates (see CLINICAL; PHARMACOLOGY-Clinical Studies section). Subsequent studies intended to demonstrate an; increase in survival have been unsuccessful. Specifically, results from a large placebo-controlled; randomized trial in patients with advanced NSCLC who progressed while receiving or within 90 days; of the last dose of chemotherapy or were intolerant to the most recent prior chemotherapy regimen, did; not show an improvement in survival (see CLINICAL PHARMACOLOGY- Clinical Studies; section).; Results from two large, controlled, randomized trials in first-line treatment of non-small cell lung; cancer showed no benefit from adding IRESSA to doublet, platinum-based chemotherapy.
DrugBank Targets:11 1. Epidermal growth factor receptor
Mechanism of Action:13 
Target: EGFR tyrosine kinase and other tyrosine kinases
Action: inhibitor
FDA: The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib; inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane; cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor; receptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells.; No clinical studies have been performed that demonstrate a correlation between EGFR receptor; expression and response to gefitinib.
9
Keytruda13 38 PEMBROLIZUMAB Merck Approved September 2014
FDA Label: Keytruda
Malady that Drug Treats: unresectable or metastatic melanoma
Indications and Usage:13 KEYTRUDA is a human programmed death receptor-1 (PD-1)-blocking; antibody indicated for the treatment of patients with unresectable or; metastatic melanoma and disease progression following ipilimumab; and, if BRAF V600 mutation positive, a BRAF inhibitor.; This indication is approved under accelerated approval based on tumor; response rate and durability of response. An improvement in survival; or disease-related symptoms has not yet been established. Continued; approval for this indication may be contingent upon verification and; description of clinical benefit in the confirmatory trials. (1)
DrugBank Targets:11 1. Programmed cell death protein 1
Mechanism of Action:13 
Target: PD-1 receptor
Action: blocks interaction with; PD-L1 and PD-L2
FDA: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell; proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.; Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with; PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the; anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in; decreased tumor growth.
10
Opdivo13 38 NIVOLUMAB Bristol-Myers Squibb Approved March 2015/ Approved December 2014
FDA Label: Opdivo
Malady that Drug Treats: metastatic squamous non-small cell lung cancer/ unresectable or metastatic melanoma
Indications and Usage:13 OPDIVO is a programmed death receptor-1 (PD-1) blocking antibody; indicated for the treatment of patients with:; unresectable or metastatic melanoma and disease progression following; ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. (1.1); This indication is approved under accelerated approval based on tumor; response rate and durability of response. Continued approval for this; indication may be contingent upon verification and description of clinical; benefit in the confirmatory trials. (1.1, 14.1); metastatic squamous non-small cell lung cancer with progression on or; after platinum-based chemotherapy. (1.2)
DrugBank Targets:11 1. Programmed cell death protein 1
Mechanism of Action:13 
Target: PD-1 receptor
Action: blocker of interaction with PD-L1 and PD-L2
FDA: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits; T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some; tumors and signaling through this pathway can contribute to inhibition of active T-cell immune; surveillance of tumors. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody; that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1; pathway-mediated inhibition of the immune response, including the anti-tumor immune; response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor; growth.
11
Photodynamic Therapy (& Photofrin)13 PORFIMER SODIUM Sanofi-aventis Approved January, 1996
Malady that Drug Treats: esophageal cancer
Indications and Usage:13 PHOTOFRIN is a photodynamic therapy drug indicated for:; Esophageal Cancer (1.1); Palliation of patients with completely obstructing esophageal cancer, or of; patients with partially obstructing esophageal cancer who, in the opinion of; their physician, cannot be satisfactorily treated with Nd:YAG laser therapy; Endobronchial Cancer (1.2); Treatment of microinvasive endobronchial non-small-cell lung cancer; (NSCLC) in patients for whom surgery and radiotherapy are not indicated; Reduction of obstruction and palliation of symptoms in patients with; completely or partially obstructing endobronchial NSCLC; High-Grade Dysplasia in Barrett s Esophagus (1.3); Ablation of high-grade dysplasia (HGD) in Barrett s esophagus (BE); patients who do not undergo esophagectomy
DrugBank Targets: -
Mechanism of Action:13 
Target: tumor cells
Action: prpagates radical reactions
FDA: Cellular damage caused by photodynamic therapy (PDT) with; PHOTOFRIN is a consequence of the propagation of radical reactions.; Radical initiation may occur after porfimer sodium absorbs light to form; a porphyrin excited state. Spin transfer from porfimer sodium to; molecular oxygen may then generate singlet oxygen. Subsequentradical reactions can form superoxide and hydroxyl radicals. Tumor; death also occurs through ischemic necrosis secondary to vascular; occlusion that appears to be partly mediated by thromboxane A2 release.; As opposed to a thermal effect, the laser treatment with porfimer; sodium induces a photochemical effect. The necrotic reaction and; associated inflammatory responses may evolve over several days.
12
Photofrin13 PORFIMER SODIUM QLT Approved January 1998
FDA Label: Photofrin
Malady that Drug Treats: Non-small cell lung cancer
Indications and Usage:13 PHOTOFRIN is a photodynamic therapy drug indicated for:; Esophageal Cancer (1.1); Palliation of patients with completely obstructing esophageal cancer, or of; patients with partially obstructing esophageal cancer who, in the opinion of; their physician, cannot be satisfactorily treated with Nd:YAG laser therapy; Endobronchial Cancer (1.2); Treatment of microinvasive endobronchial non-small-cell lung cancer; (NSCLC) in patients for whom surgery and radiotherapy are not indicated; Reduction of obstruction and palliation of symptoms in patients with; completely or partially obstructing endobronchial NSCLC; High-Grade Dysplasia in Barrett s Esophagus (1.3); Ablation of high-grade dysplasia (HGD) in Barrett s esophagus (BE); patients who do not undergo esophagectomy
DrugBank Targets:11 1. Low-density lipoprotein receptor; 2. High affinity immunoglobulin gamma Fc receptor I
Mechanism of Action:13 
Target: tumor cells
Action: prpagates radical reactions
FDA: Cellular damage caused by photodynamic therapy (PDT) with; PHOTOFRIN is a consequence of the propagation of radical reactions.; Radical initiation may occur after porfimer sodium absorbs light to form; a porphyrin excited state. Spin transfer from porfimer sodium to; molecular oxygen may then generate singlet oxygen. Subsequentradical reactions can form superoxide and hydroxyl radicals. Tumor; death also occurs through ischemic necrosis secondary to vascular; occlusion that appears to be partly mediated by thromboxane A2 release.; As opposed to a thermal effect, the laser treatment with porfimer; sodium induces a photochemical effect. The necrotic reaction and; associated inflammatory responses may evolve over several days.
13
Tarceva13 38 ERLOTINIB HYDROCHLORIDE Genentech, OSI Pharmaceuticals Approved November, 2004
FDA Label: Tarceva
Malady that Drug Treats: Non-small cell lung cancer
Indications and Usage:13 TARCEVA is a kinase inhibitor indicated for:; First-line treatment of patients with metastatic non-small cell lung; cancer (NSCLC) whose tumors have epidermal growth factor receptor; (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as; detected by an FDA-approved test. (1.1); Maintenance treatment of patients with locally advanced or metastatic; NSCLC whose disease has not progressed after four cycles of platinumbased; first-line chemotherapy. (1.1); Treatment of locally advanced or metastatic NSCLC after failure of at; least one prior chemotherapy regimen. (1.1); First-line treatment of patients with locally advanced, unresectable or; metastatic pancreatic cancer, in combination with gemcitabine. (1.2)
DrugBank Targets:11 1. Epidermal growth factor receptor; 2. Nuclear receptor subfamily 1 group I member 2
Mechanism of Action:13 
Target: Human Epidermal Growth Factor Receptor Type 1/Epidermal Growth Factor Receptor (HER1/EGFR) tyrosine kinase
Action: inhibitor
FDA: Epidermal growth factor receptor (EGFR) is expressed on the cell surface of both normal and cancer cells. In some tumor cells signaling; through this receptor plays a role in tumor cell survival and proliferation irrespective of EGFR mutation status. Erlotinib reversibly; inhibits the kinase activity of EGFR, preventing autophosphorylation of tyrosine residues associated with the receptor and thereby; inhibiting further downstream signaling. Erlotinib binding affinity for EGFR exon 19 deletion or exon 21 (L858R) mutations is higher; than its affinity for the wild type receptor. Erlotinib inhibition of other tyrosine kinase receptors has not been fully characterized.
14
Taxol13 38 PACLITAXEL Bristol-Myers Squibb Approved August 1997
FDA Label: Taxol
Malady that Drug Treats: Kaposi's Sarcoma
Indications and Usage:13 Paclitaxel Injection, USP is indicated as subsequent therapy for the treatment of advanced carcinoma of; the ovary. As first-line therapy, Paclitaxel Injection, USP is indicated in combination with cisplatin.; Paclitaxel Injection, USP is indicated for the adjuvant treatment of node-positive breast cancer; administered sequentially to standard doxorubicin-containing combination chemotherapy.. In the clinical; trial, there was an overall favorable effect on disease-free and overall survival in the total population of; patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and; progesterone receptor-negative tumors (see CLINICAL STUDIES, Breast Carcinoma).; Paclitaxel Injection, USP is indicated for the treatment of breast cancer after failure of combination; chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy; should have included an anthracycline unless clinically contraindicated.; Paclitaxel Injection, USP, in combination with cisplatin, is indicated for the first-line treatment of nonsmall; cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation; therapy.; Paclitaxel Injection, USP is indicated for the second-line treatment of AIDS-related Kaposi s sarcoma.
DrugBank Targets:11 1. Apoptosis regulator Bcl-2; 2. Tubulin beta-1 chain; 3. Nuclear receptor subfamily 1 group I member 2; 4. Microtubule-associated protein 4; 5. Microtubule-associated protein 2; 6. Microtubule-associated protein tau
Mechanism of Action:13 
Target: microtubules
Action: promoter of assembly & preventor of depolymerization
FDA: Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin; dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition; of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and; mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or  bundles of microtubules; throughout the cell cycle and multiple asters of microtubules during mitosis.; Following intravenous administration of paclitaxel, paclitaxel plasma concentrations declined in a; biphasic manner. The initial rapid decline represents distribution to the peripheral compartment and; elimination of the drug. The later phase is due, in part, to a relatively slow efflux of paclitaxel from the; peripheral compartment.; Pharmacokinetic parameters of paclitaxel following 3- and 24-hour infusions of paclitaxel at dose levels; of 135 and 175 mg/m2; were determined in a Phase 3 randomized study in ovarian cancer patients and are; summarized in the following table:
15
Taxotere13 38 DOCETAXEL Rhone Poulenc Rorer Approved May 1996
FDA Label: Taxotere
Malady that Drug Treats: breast cancer
Indications and Usage:13 TAXOTERE is a microtubule inhibitor indicated for:; Breast Cancer (BC): single agent for locally advanced or metastatic BC; after chemotherapy failure; and with doxorubicin and; cyclophosphamide as adjuvant treatment of operable node-positive BC; (1.1); Non-Small Cell Lung Cancer (NSCLC): single agent for locally; ; advanced or metastatic NSCLC after platinum therapy failure; and; ; with cisplatin for unresectable, locally advanced or metastatic; untreated NSCLC (1.2); ; Hormone Refractory Prostate Cancer (HRPC): with prednisone in; androgen independent (hormone refractory) metastatic prostate cancer; (1.3); Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for; untreated, advanced GC, including the gastroesophageal junction (1.4); Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN):; with cisplatin and fluorouracil for induction treatment of locally; advanced SCCHN (1.5)
DrugBank Targets:11 1. Tubulin beta-1 chain; 2. Apoptosis regulator Bcl-2; 3. Microtubule-associated protein 2; 4. Microtubule-associated protein 4; 5. Microtubule-associated protein tau; 6. Nuclear receptor subfamily 1 group I member 2
Mechanism of Action:13 
Target: free tubulin
Action: promoter of assembly
FDA: Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is; essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the; assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. This; leads to the production of microtubule bundles without normal function and to the stabilization of; microtubules, which results in the inhibition of mitosis in cells. Docetaxel s binding to microtubules; does not alter the number of protofilaments in the bound microtubules, a feature which differs from most; spindle poisons currently in clinical use.
16
Xalkori13 38 CRIZOTINIB Pfizer Approved August of 2011
FDA Label: Xalkori
Malady that Drug Treats: ALK+ non-small cell lung cancer
Indications and Usage:13 XALKORI is a kinase inhibitor indicated for the treatment of patients with ; metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic; lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (1)
DrugBank Targets:11 1. ALK tyrosine kinase receptor; 2. Hepatocyte growth factor receptor
Mechanism of Action:13 
Target: receptor tyrosine kinases
Action: inhibitor
FDA: Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor; (HGFR, c-Met), ROS1 (c-ros), and Recepteur d Origine Nantais (RON). Translocations can affect the ALK; gene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results in; activation and dysregulation of the gene s expression and signaling which can contribute to increased cell; proliferation and survival in tumors expressing these proteins. Crizotinib demonstrated concentration-dependent; inhibition of ALK, ROS1, and c-Met phosphorylation in cell-based assays using tumor cell lines and; demonstrated antitumor activity in mice bearing tumor xenografts that expressed EML4- or NPM-ALK fusion; proteins or c-Met.
17
Zometa13 38 ZOLEDRONIC ACID Novartis Approved August 2001/ Approved February 2002
FDA Label: Zometa
Malady that Drug Treats: Hypercalcemia of malignancy/ Multiple myeloma; bone metastases from solid tumors
Indications and Usage:13 Zometa is a bisphosphonate indicated for the treatment of:; Hypercalcemia of malignancy. (1.1); Patients with multiple myeloma and patients with documented bone; metastases from solid tumors, in conjunction with standard antineoplastic; therapy. Prostate cancer should have progressed after treatment with at; least one hormonal therapy. (1.2); Important limitation of use: The safety and efficacy of Zometa has not been; established for use in hyperparathyroidism or nontumor-related; hypercalcemia. (1.3)
DrugBank Targets:11 1. Farnesyl pyrophosphate synthase; 2. Geranylgeranyl pyrophosphate synthase; 3. Hydroxylapatite
Mechanism of Action:13 
Target: bone resorption
Action: inhibitor
FDA: The principal pharmacologic action of zoledronic acid is inhibition of bone resorption. Although the; antiresorptive mechanism is not completely understood, several factors are thought to contribute to this action.; In vitro, zoledronic acid inhibits osteoclastic activity and induces osteoclast apoptosis. Zoledronic acid also; blocks the osteoclastic resorption of mineralized bone and cartilage through its binding to bone. Zoledronic acid; inhibits the increased osteoclastic activity and skeletal calcium release induced by various stimulatory factors; released by tumors.
18
Zykadia13 38 CERITINIB Novartis Approved April 2014
FDA Label: Zykadia
Malady that Drug Treats: ALK+ metastatic non-small cell lung cancer
Indications and Usage:13 ZYKADIA is a kinase inhibitor indicated for the treatment of patients with; anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung; cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This; indication is approved under accelerated approval based on tumor response; rate and duration of response. An improvement in survival or disease-related; symptoms has not been established. Continued approval for this indication; may be contingent upon verification and description of clinical benefit in; confirmatory trials. (1)
DrugBank Targets:11 1. ALK tyrosine kinase receptor
Mechanism of Action:13 
Target: ALK, insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1
Action: kinase inhibitor
FDA: Ceritinib is a kinase inhibitor. Targets of ceritinib inhibition identified in either biochemical or cellular assays at clinically; relevant concentrations include ALK, insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1.; Among these, ceritinib is most active against ALK. Ceritinib inhibited autophosphorylation of ALK, ALK-mediated; phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells in in vitro; and in vivo assays.; Ceritinib inhibited the in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins and; demonstrated dose-dependent inhibition of EML4-ALK-positive NSCLC xenograft growth in mice and rats. Ceritinib; exhibited dose-dependent anti-tumor activity in mice bearing EML4-ALK-positive NSCLC xenografts with demonstrated; resistance to crizotinib, at concentrations within a clinically relevant range.

Drug clinical trials:

Search ClinicalTrials for Lung Cancer

Search NIH Clinical Center for Lung Cancer

Inferred drug relations via UMLS61/NDF-RT40:

Genetic Tests for Lung Cancer

About this section

Genetic tests related to Lung Cancer:

id Genetic test Affiliating Genes
1 Lung Cancer20 22 GSTM1
2 Non-Small Cell Lung Cancer22

Anatomical Context for Lung Cancer

About this section

MalaCards organs/tissues related to Lung Cancer:

31
Lung, Skeletal muscle, Endothelial, Lymph node, Breast, Bone, Testes, Brain, T cells, Neutrophil, Prostate, Colon, Testis, Myeloid, Bone marrow, Monocytes, Liver, Thyroid, B cells, Kidney, Heart, Pituitary, Smooth muscle, Bronchial epithelium, Placenta, Nk cells, Whole blood, Small intestine, Salivary gland, Skin, Spinal cord, Tongue

FMA organs/tissues related to Lung Cancer:

14
The lung

Animal Models for Lung Cancer or affiliated genes

About this section

MGI Mouse Phenotypes related to Lung Cancer:

35 (show all 20)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000538411.8PARK2, EGFR, ERCC6, ERBB2, RASSF1, GSTM1
2MP:000537611.8PIK3CA, ERBB2, FASLG, IRF1, PARK2, ERCC6
3MP:001076811.7IRF1, FASLG, MAP3K8, CASP8, DLC1, RASSF1
4MP:000538511.7RASSF1, DLC1, FASLG, CASP8, MAP3K8, IRF1
5MP:000363111.6ERCC6, PARK2, KRAS, EGFR, FASLG, ERBB2
6MP:000200611.5RASSF1, KRAS, ERCC6, ERBB2, EGFR, IRF1
7MP:001077111.5EGFR, KRAS, ERCC6, ERBB2, CASP8, FASLG
8MP:000538711.5MAP3K8, CASP8, ERCC6, KRAS, EGFR, RASSF1
9MP:000537811.4PIK3CA, ERBB2, ERCC6, KRAS, EGFR, BRAF
10MP:000536911.3ERCC6, BRAF, PARK2, CASP8, ERBB2, KRAS
11MP:000539711.3DLC1, ERCC6, KRAS, EGFR, MAP3K8, FASLG
12MP:000287311.3FASLG, DLC1, BRAF, IRF1, RASSF1, EGFR
13MP:000538811.2FASLG, CASP8, ERBB2, KRAS, EGFR, PARK2
14MP:000537911.1PIK3CA, BRAF, EGFR, KRAS, ERBB2, CASP8
15MP:000539011.1IRF1, FASLG, ERBB2, ERCC6, EGFR, BRAF
16MP:000538011.1PIK3CA, KRAS, ERBB2, DLC1, CASP8, EGFR
17MP:000537010.9EGFR, KRAS, ERCC6, BRAF, CASP8, FASLG
18MP:000539110.9EGFR, KRAS, FASLG, BRAF, PIK3CA, ERCC6
19MP:000536710.8BRAF, FASLG, CASP8, KRAS, EGFR, IRF1
20MP:000538110.6ERBB2, BRAF, FASLG, MAP3K8, KRAS, EGFR

Publications for Lung Cancer

About this section

Articles related to Lung Cancer:

(show top 50)    (show all 10325)
idTitleAuthorsYear
1
Can statins reduce risk of lung cancer, especially among elderly people? A meta-analysis. (24385695)
2013
2
Relationship between gene polymorphisms of two cytokine genes (TNF-I+ and IL-6) and occurring of lung cancers in the ethnic group Han of China. (23100065)
2013
3
Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation. (23591159)
2013
4
let-7b and miR-126 are down-regulated in tumor tissue and correlate with microvessel density and survival outcomes in non--small--cell lung cancer. (23029111)
2012
5
Expression of heme oxygenase-1 in non-small cell lung cancer (NSCLC) and its correlation with clinical data. (22418244)
2012
6
Relationship among the expression of lymphatic vessel density, microvessel density, carcinoembryonic antigenic mRNA, KAI1, and Kiss-1, and prognosis in patients with non-small cell lung cancer]. (22681921)
2012
7
Protein arginine methyltransferase 5 is essential for growth of lung cancer cells. (22708516)
2012
8
Structural basis of tumor suppressor in lung cancer 1 (TSLC1) binding to differentially expressed in adenocarcinoma of the lung (DAL- 1/4.1B). (21131357)
2011
9
Association of FOXP3 expression with non-small cell lung cancer. (21617226)
2011
10
P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment. (21616632)
2011
11
Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. (20828860)
2011
12
High temperature requirement A3 (HtrA3) promotes etoposide- and cisplatin-induced cytotoxicity in lung cancer cell lines. (20154083)
2010
13
XRCC1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis. (19329222)
2009
14
Breast cancer metastasis suppressor 1 (BRMS1) suppresses metastasis and correlates with improved patient survival in non-small cell lung cancer. (19111386)
2009
15
Age-associated changes of extracellular matrix collagen impair lung cancer cell migration. (19109409)
2009
16
Association of XPD polymorphisms with severe toxicity in non-small cell lung cancer patients in a Chinese population. (19458053)
2009
17
Proteomics and pathway analysis identifies JNK signaling as critical for high linear energy transfer radiation-induced apoptosis in non-small lung cancer cells. (19168796)
2009
18
2008 Meeting of the National Lung Cancer Partnership: a summary of meeting highlights. (19395913)
2009
19
Association of DNA repair gene XRCC1 and lung cancer susceptibility among nonsmoking Chinese women. (19061777)
2009
20
Blazein of a new steroid isolated from Agaricus blazei Murrill (himematsutake) induces cell death and morphological change indicative of apoptotic chromatin condensation in human lung cancer LU99 and stomach cancer KATO III cells. (19020714)
2008
21
Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. (18854777)
2008
22
Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients. (18715616)
2008
23
Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. (18212743)
2008
24
Mediastinal lymphatic drainage from pulmonary lobe based on CT observations of histoplasmosis: implications for minimal N2 disease of non-small-cell lung cancer. (17952543)
2007
25
Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients. (17436410)
2007
26
In vitro simulation study of individualized chemotherapy in lung cancer. (17625370)
2007
27
Hypoxia-inducible factor-1alpha suppressing apoptosis and increasing tolerance of lung cancer cells to chemotherapy. (17219956)
2006
28
Enhanced expression of VEGF following bFGF inhibition in non-small cell lung cancer cell lines. (16934908)
2006
29
Consequences of chemoresistance for the herpes simplex virus thymidine kinase/ganciclovir-induced bystander effect in a human small cell lung cancer cell line model. (15816546)
2005
30
Serum carcinoembryonic antigen level in pN1 non-small cell lung cancer patients. (16101187)
2005
31
Role of IL-6 in neuroendocrine differentiation and chemosensitivity of non-small cell lung cancer. (15894559)
2005
32
Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. (16170027)
2005
33
Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. (15746151)
2005
34
Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial. (15301877)
2004
35
Association between glutathione S-transferase p1 polymorphisms and lung cancer risk in Caucasians: a case-control study. (12660004)
2003
36
Induction of RECK by nonsteroidal anti-inflammatory drugs in lung cancer cells. (12447698)
2002
37
Association of L-myc polymorphism with lung cancer susceptibility and prognosis in relation to age-selected controls and stratified cases. (11955646)
2002
38
IL-12-induced production of IL-10 and interferon-gamma by mononuclear cells in lung cancer-associated malignant pleural effusions. (11804690)
2002
39
A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. (11691799)
2001
40
Clinical significance of caspase-3 expression in pathologic-stage I, nonsmall-cell lung cancer. (11992386)
2001
41
p21 is associated with cyclin D1, p16INK4a and pRb expression in resectable non-small cell lung cancer. (10762631)
2000
42
Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) gene therapy protection of the esophagus from chemoradiotherapy damage during treatment of locally unresectable non-small-cell lung cancer (NSCLC). (14733636)
2000
43
Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. (10495436)
1999
44
MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. (9930070)
1998
45
72-kD (MMP-2) and 92-kD (MMP-9) type IV collagenase production and activity in different histologic types of lung cancer cells. (9577961)
1998
46
Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. (9036871)
1997
47
Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. (9228385)
1997
48
Phase I study of cisplatin, ifosfamide and CPT11 with granulocyte colony-stimulating factor support in advanced non-small cell lung cancer]. (8831740)
1996
49
Altered HLA class I expression in non-small cell lung cancer is independent of c-myc activation. (1849792)
1991
50
Epidemiologic and histologic observations on lung cancer in pneumoconiosis population. (7172143)
1982

Variations for Lung Cancer

About this section

UniProtKB/Swiss-Prot genetic disease variations for Lung Cancer:

63
id Symbol AA change Variation ID SNP ID
1BRAFp.Gly466ValVAR_018512
2BRAFp.Leu597ArgVAR_018513
3MXRA5p.Ser862AsnVAR_072408
4SLC22A18p.Ser233PheVAR_024062

Clinvar genetic disease variations for Lung Cancer:

5
id Gene Variation Type Significance SNP ID Assembly Location
1KRASNM_033360.3(KRAS): c.34G> T (p.Gly12Cys)single nucleotide variantPathogenic, drug responsers121913530GRCh37Chr 12, 25398285: 25398285
2PIK3CANM_006218.2(PIK3CA): c.3140A> G (p.His1047Arg)single nucleotide variantPathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
3PIK3CANM_006218.2(PIK3CA): c.1633G> A (p.Glu545Lys)single nucleotide variantPathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
4BRAFNM_004333.4(BRAF): c.1789C> G (p.Leu597Val)single nucleotide variantPathogenicrs121913369GRCh37Chr 7, 140453146: 140453146
5FASLGNM_000639.1(FASLG): c.-844C=single nucleotide variantPathogenic, risk factorrs763110GRCh37Chr 1, 172627498: 172627498
6PPP2R1BNM_181699.2(PPP2R1B): c.269G> A (p.Gly90Asp)single nucleotide variantPathogenicrs1805076GRCh37Chr 11, 111635566: 111635566
7SLC22A18NM_183233.2(SLC22A18): c.698C> T (p.Ser233Phe)single nucleotide variantPathogenicrs121909071GRCh37Chr 11, 2939260: 2939260

Cosmic variations for Lung Cancer:

6 (show all 5,357)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
143896TP53lung,NS,carcinoma,adenocarcinoma3
210810TP53lung,NS,carcinoma,adenocarcinoma3
311306TP53lung,NS,carcinoma,adenocarcinoma3
444945TP53lung,NS,carcinoma,adenocarcinoma3
511450TP53lung,NS,carcinoma,adenocarcinoma3
644126TP53lung,NS,carcinoma,adenocarcinoma3
744956TP53lung,NS,carcinoma,adenocarcinoma3
811059TP53lung,NS,carcinoma,adenocarcinoma3
910651TP53lung,NS,carcinoma,adenocarcinoma3
1011451TP53lung,NS,carcinoma,adenocarcinoma3
1143555TP53lung,NS,carcinoma,adenocarcinoma3
1243995TP53lung,NS,carcinoma,adenocarcinoma3
1311514TP53lung,NS,carcinoma,adenocarcinoma3
14378685TP53lung,NS,carcinoma,adenocarcinoma3
1510726TP53lung,NS,carcinoma,adenocarcinoma3
1610646TP53lung,NS,carcinoma,adenocarcinoma3
17674226TP53lung,NS,carcinoma,adenocarcinoma3
1844102TP53lung,NS,carcinoma,adenocarcinoma3
1945822TP53lung,NS,carcinoma,adenocarcinoma3
2044525TP53lung,NS,carcinoma,adenocarcinoma3
2143989TP53lung,NS,carcinoma,adenocarcinoma3
2243973TP53lung,NS,carcinoma,adenocarcinoma3
2344776TP53lung,NS,carcinoma,adenocarcinoma3
2410659TP53lung,NS,carcinoma,adenocarcinoma3
2510768TP53lung,NS,carcinoma,adenocarcinoma3
2610647TP53lung,NS,carcinoma,adenocarcinoma3
27145025TP53lung,NS,carcinoma,adenocarcinoma3
2811287TP53lung,NS,carcinoma,adenocarcinoma3
2943665TP53lung,NS,carcinoma,adenocarcinoma3
3043966TP53lung,NS,carcinoma,adenocarcinoma3
3112732TP53lung,NS,carcinoma,adenocarcinoma3
3244801TP53lung,NS,carcinoma,adenocarcinoma3
3348817TP53lung,NS,carcinoma,adenocarcinoma3
3443708TP53lung,NS,carcinoma,adenocarcinoma3
3543836TP53lung,NS,carcinoma,adenocarcinoma3
3643687TP53lung,NS,carcinoma,adenocarcinoma3
37144150TP53lung,NS,carcinoma,adenocarcinoma3
3846057TP53lung,NS,carcinoma,adenocarcinoma3
3943878TP53lung,NS,carcinoma,adenocarcinoma3
4010912TP53lung,NS,carcinoma,adenocarcinoma3
4143652TP53lung,NS,carcinoma,adenocarcinoma3
4211063TP53lung,NS,carcinoma,adenocarcinoma3
4310709TP53lung,NS,carcinoma,adenocarcinoma3
44144153TP53lung,NS,carcinoma,adenocarcinoma3
4543692TP53lung,NS,carcinoma,adenocarcinoma3
4610716TP53lung,NS,carcinoma,adenocarcinoma3
4745268TP53lung,NS,carcinoma,adenocarcinoma3
4810743TP53lung,NS,carcinoma,adenocarcinoma3
4910834TP53lung,NS,carcinoma,adenocarcinoma3
5011123TP53lung,NS,carcinoma,adenocarcinoma3
5148816TP53lung,NS,carcinoma,adenocarcinoma3
5244571TP53lung,NS,carcinoma,adenocarcinoma3
5311449TP53lung,NS,carcinoma,adenocarcinoma3
5410769TP53lung,NS,carcinoma,adenocarcinoma3
5543846TP53lung,NS,carcinoma,adenocarcinoma3
5645674TP53lung,NS,carcinoma,adenocarcinoma3
5711181TP53lung,NS,carcinoma,adenocarcinoma3
5843689TP53lung,NS,carcinoma,adenocarcinoma3
5996438TP53lung,NS,carcinoma,adenocarcinoma3
6011188TP53lung,NS,carcinoma,adenocarcinoma3
611717459TP53lung,NS,carcinoma,adenocarcinoma3
6244227TP53lung,NS,carcinoma,adenocarcinoma3
6343962TP53lung,NS,carcinoma,adenocarcinoma3
6410887TP53lung,NS,carcinoma,adenocarcinoma3
6544004TP53lung,NS,carcinoma,adenocarcinoma3
6610812TP53lung,NS,carcinoma,adenocarcinoma3
6710988TP53lung,NS,carcinoma,adenocarcinoma3
6844944TP53lung,NS,carcinoma,adenocarcinoma3
6910717TP53lung,NS,carcinoma,adenocarcinoma3
7043861TP53lung,NS,carcinoma,adenocarcinoma3
7111152TP53lung,NS,carcinoma,adenocarcinoma3
7244326TP53lung,NS,carcinoma,adenocarcinoma3
7345483TP53lung,NS,carcinoma,adenocarcinoma3
7443967TP53lung,NS,carcinoma,adenocarcinoma3
7543965TP53lung,NS,carcinoma,adenocarcinoma3
7643906TP53lung,NS,carcinoma,adenocarcinoma3
7711114TP53lung,NS,carcinoma,adenocarcinoma3
7810715TP53lung,NS,carcinoma,adenocarcinoma3
7944580TP53lung,NS,carcinoma,adenocarcinoma3
8044782TP53lung,NS,carcinoma,adenocarcinoma3
8145361TP53lung,NS,carcinoma,adenocarcinoma3
8210672TP53lung,NS,carcinoma,adenocarcinoma3
8344547TP53lung,NS,carcinoma,adenocarcinoma3
8443606TP53lung,NS,carcinoma,adenocarcinoma3
8510690TP53lung,NS,carcinoma,adenocarcinoma3
8611087TP53lung,NS,carcinoma,adenocarcinoma3
8710941TP53lung,NS,carcinoma,adenocarcinoma3
8811205TP53lung,NS,carcinoma,adenocarcinoma3
8910667TP53lung,NS,carcinoma,adenocarcinoma3
9011198TP53lung,NS,carcinoma,adenocarcinoma3
9144433TP53lung,NS,carcinoma,adenocarcinoma3
921717457TP53lung,NS,carcinoma,adenocarcinoma3
9345825TP53lung,NS,carcinoma,adenocarcinoma3
9444094TP53lung,NS,carcinoma,adenocarcinoma3
9543615TP53lung,NS,carcinoma,adenocarcinoma3
9611564TP53lung,NS,carcinoma,adenocarcinoma3
9744002TP53lung,NS,carcinoma,adenocarcinoma3
9843651TP53lung,NS,carcinoma,adenocarcinoma3
9943559TP53lung,NS,carcinoma,adenocarcinoma3
10010863TP53lung,NS,carcinoma,adenocarcinoma3
10110760TP53lung,NS,carcinoma,adenocarcinoma3
10244327TP53lung,NS,carcinoma,adenocarcinoma3
10345286TP53lung,NS,carcinoma,adenocarcinoma3
10443582TP53lung,NS,carcinoma,adenocarcinoma3
10510718TP53lung,NS,carcinoma,adenocarcinoma3
10610891TP53lung,NS,carcinoma,adenocarcinoma3
10744415TP53lung,NS,carcinoma,adenocarcinoma3
10843970TP53lung,NS,carcinoma,adenocarcinoma3
10911356TP53lung,NS,carcinoma,adenocarcinoma3
11011524TP53lung,NS,carcinoma,adenocarcinoma3
11110725TP53lung,NS,carcinoma,adenocarcinoma3
112371784TP53lung,NS,carcinoma,adenocarcinoma3
11344214TP53lung,NS,carcinoma,adenocarcinoma3
11410889TP53lung,NS,carcinoma,adenocarcinoma3
11510771TP53lung,NS,carcinoma,adenocarcinoma3
1166815TP53lung,NS,carcinoma,adenocarcinoma3
11710758TP53lung,NS,carcinoma,adenocarcinoma3
11810662TP53lung,NS,carcinoma,adenocarcinoma3
11943596TP53lung,NS,carcinoma,adenocarcinoma3
12045729TP53lung,NS,carcinoma,adenocarcinoma3
12144033TP53lung,NS,carcinoma,adenocarcinoma3
12211491TP53lung,NS,carcinoma,adenocarcinoma3
12344877TP53lung,NS,carcinoma,adenocarcinoma3
12444962TP53lung,NS,carcinoma,adenocarcinoma3
12510995TP53lung,NS,carcinoma,adenocarcinoma3
12610813TP53lung,NS,carcinoma,adenocarcinoma3
12743968TP53lung,NS,carcinoma,adenocarcinoma3
12811210TP53lung,NS,carcinoma,adenocarcinoma3
12944303TP53lung,NS,carcinoma,adenocarcinoma3
1306549TP53lung,NS,carcinoma,adenocarcinoma3
13144935TP53lung,NS,carcinoma,adenocarcinoma3
13210742TP53lung,NS,carcinoma,adenocarcinoma3
13310777TP53lung,NS,carcinoma,adenocarcinoma3
13410687TP53lung,NS,carcinoma,adenocarcinoma3
13543550TP53lung,NS,carcinoma,adenocarcinoma3
13643755TP53lung,NS,carcinoma,adenocarcinoma3
13710749TP53lung,NS,carcinoma,adenocarcinoma3
13810648TP53lung,NS,carcinoma,adenocarcinoma3
13910867TP53lung,NS,carcinoma,adenocarcinoma3
14010722TP53lung,NS,carcinoma,adenocarcinoma3
14110893TP53lung,NS,carcinoma,adenocarcinoma3
14244137TP53lung,NS,carcinoma,adenocarcinoma3
14344240TP53lung,NS,carcinoma,adenocarcinoma3
14410939TP53lung,NS,carcinoma,adenocarcinoma3
14510794TP53lung,NS,carcinoma,adenocarcinoma3
14644103TP53lung,NS,carcinoma,adenocarcinoma3
14713165TP53lung,NS,carcinoma,adenocarcinoma3
14811081TP53lung,NS,carcinoma,adenocarcinoma3
14910714TP53lung,NS,carcinoma,adenocarcinoma3
150562608TP53lung,NS,carcinoma,adenocarcinoma3
15111606TP53lung,NS,carcinoma,adenocarcinoma3
152330687TP53lung,NS,carcinoma,adenocarcinoma3
15310668TP53lung,NS,carcinoma,adenocarcinoma3
15411183TP53lung,NS,carcinoma,adenocarcinoma3
15543700TP53lung,NS,carcinoma,adenocarcinoma3
156144210TP53lung,NS,carcinoma,adenocarcinoma3
15710779TP53lung,NS,carcinoma,adenocarcinoma3
15810958TP53lung,NS,carcinoma,adenocarcinoma3
15943777TP53lung,NS,carcinoma,adenocarcinoma3
16010785TP53lung,NS,carcinoma,adenocarcinoma3
16110645TP53lung,NS,carcinoma,adenocarcinoma3
16243871TP53lung,NS,carcinoma,adenocarcinoma3
16310905TP53lung,NS,carcinoma,adenocarcinoma3
16411148TP53lung,NS,carcinoma,adenocarcinoma3
1656932TP53lung,NS,carcinoma,adenocarcinoma3
16645997TP53lung,NS,carcinoma,adenocarcinoma3
16743947TP53lung,NS,carcinoma,adenocarcinoma3
16844481TP53lung,NS,carcinoma,adenocarcinoma3
16943900TP53lung,NS,carcinoma,adenocarcinoma3
170562637TP53lung,NS,carcinoma,adenocarcinoma3
17110731TP53lung,NS,carcinoma,adenocarcinoma3
17211498TP53lung,NS,carcinoma,adenocarcinoma3
17343963TP53lung,NS,carcinoma,adenocarcinoma3
17410701TP53lung,NS,carcinoma,adenocarcinoma3
17544508TP53lung,NS,carcinoma,adenocarcinoma3
17645820TP53lung,NS,carcinoma,adenocarcinoma3
17744380TP53lung,NS,carcinoma,adenocarcinoma3
17844224TP53lung,NS,carcinoma,adenocarcinoma3
17910757TP53lung,NS,carcinoma,adenocarcinoma3
18011582TP53lung,NS,carcinoma,adenocarcinoma3
18111071TP53lung,NS,carcinoma,adenocarcinoma3
18210724TP53lung,NS,carcinoma,adenocarcinoma3
18344026TP53lung,NS,carcinoma,adenocarcinoma3
18410670TP53lung,NS,carcinoma,adenocarcinoma3
18511196TP53lung,NS,carcinoma,adenocarcinoma3
186210757TP53lung,NS,carcinoma,adenocarcinoma3
18743697TP53lung,NS,carcinoma,adenocarcinoma3
18810704TP53lung,NS,carcinoma,adenocarcinoma3
18910859TP53lung,NS,carcinoma,adenocarcinoma3
19010817TP53lung,NS,carcinoma,adenocarcinoma3
1911717458TP53lung,NS,carcinoma,adenocarcinoma3
19244546TP53lung,NS,carcinoma,adenocarcinoma3
19343814TP53lung,NS,carcinoma,adenocarcinoma3
19443629TP53lung,NS,carcinoma,adenocarcinoma3
19510992TP53lung,NS,carcinoma,adenocarcinoma3
19611516TP53lung,NS,carcinoma,adenocarcinoma3
19711411TP53lung,NS,carcinoma,adenocarcinoma3
19810814TP53lung,NS,carcinoma,adenocarcinoma3
199133677TP53lung,NS,carcinoma,adenocarcinoma3
20043706TP53lung,NS,carcinoma,adenocarcinoma3
20145413TP53lung,NS,carcinoma,adenocarcinoma3
20243778TP53lung,NS,carcinoma,adenocarcinoma3
20310739TP53lung,NS,carcinoma,adenocarcinoma3
20443650TP53lung,NS,carcinoma,adenocarcinoma3
20545360TP53lung,NS,carcinoma,adenocarcinoma3
20610660TP53lung,NS,carcinoma,adenocarcinoma3
20710656TP53lung,NS,carcinoma,adenocarcinoma3
20810808TP53lung,NS,carcinoma,adenocarcinoma3
20913005EGFRlung,NS,carcinoma,adenocarcinoma3
21013006EGFRlung,NS,carcinoma,adenocarcinoma3
21125090EGFRlung,NS,carcinoma,adenocarcinoma3
21253194EGFRlung,NS,carcinoma,adenocarcinoma3
2136219EGFRlung,NS,carcinoma,adenocarcinoma3
21428515EGFRlung,NS,carcinoma,adenocarcinoma3
21586999EGFRlung,NS,carcinoma,adenocarcinoma3
21628513EGFRlung,NS,carcinoma,adenocarcinoma3
217379422EGFRlung,NS,carcinoma,adenocarcinoma3
21828509EGFRlung,NS,carcinoma,adenocarcinoma3
21926413EGFRlung,NS,carcinoma,adenocarcinoma3
2201716255EGFRlung,NS,carcinoma,adenocarcinoma3
2211666924EGFRlung,NS,carcinoma,adenocarcinoma3
22228600EGFRlung,NS,carcinoma,adenocarcinoma3
2231235366EGFRlung,NS,carcinoma,adenocarcinoma3
22434155EGFRlung,NS,carcinoma,adenocarcinoma3
2253718345EGFRlung,NS,carcinoma,adenocarcinoma3
22628601EGFRlung,NS,carcinoma,adenocarcinoma3
22728606EGFRlung,NS,carcinoma,adenocarcinoma3
22853180EGFRlung,NS,carcinoma,adenocarcinoma3
22934160EGFRlung,NS,carcinoma,adenocarcinoma3
230133107EGFRlung,NS,carcinoma,adenocarcinoma3
23128607EGFRlung,NS,carcinoma,adenocarcinoma3
23227535EGFRlung,NS,carcinoma,adenocarcinoma3
233214351EGFRlung,NS,carcinoma,adenocarcinoma3
23412374EGFRlung,NS,carcinoma,adenocarcinoma3
23529577EGFRlung,NS,carcinoma,adenocarcinoma3
23628512EGFRlung,NS,carcinoma,adenocarcinoma3
23730753EGFRlung,NS,carcinoma,adenocarcinoma3
23828574EGFRlung,NS,carcinoma,adenocarcinoma3
23927568EGFRlung,NS,carcinoma,adenocarcinoma3
24013183EGFRlung,NS,carcinoma,adenocarcinoma3
24126704EGFRlung,NS,carcinoma,adenocarcinoma3
24212373EGFRlung,NS,carcinoma,adenocarcinoma3
243214350EGFRlung,NS,carcinoma,adenocarcinoma3
244219795EGFRlung,NS,carcinoma,adenocarcinoma3
24553179EGFRlung,NS,carcinoma,adenocarcinoma3
24613182EGFRlung,NS,carcinoma,adenocarcinoma3
24714069EGFRlung,NS,carcinoma,adenocarcinoma3
24820896EGFRlung,NS,carcinoma,adenocarcinoma3
2491235397EGFRlung,NS,carcinoma,adenocarcinoma3
25017570EGFRlung,NS,carcinoma,adenocarcinoma3
2511666920EGFRlung,NS,carcinoma,adenocarcinoma3
2521666921EGFRlung,NS,carcinoma,adenocarcinoma3
25326509EGFRlung,NS,carcinoma,adenocarcinoma3
25413008EGFRlung,NS,carcinoma,adenocarcinoma3
25513185EGFRlung,NS,carcinoma,adenocarcinoma3
256133708EGFRlung,NS,carcinoma,adenocarcinoma3
2571651574EGFRlung,NS,carcinoma,adenocarcinoma3
25888795EGFRlung,NS,carcinoma,adenocarcinoma3
25927102EGFRlung,NS,carcinoma,adenocarcinoma3
26022991EGFRlung,NS,carcinoma,adenocarcinoma3
261341496EGFRlung,NS,carcinoma,adenocarcinoma3
262133627EGFRlung,NS,carcinoma,adenocarcinoma3
26328537EGFRlung,NS,carcinoma,adenocarcinoma3
264133628EGFRlung,NS,carcinoma,adenocarcinoma3
26518441EGFRlung,NS,carcinoma,adenocarcinoma3
26627110EGFRlung,NS,carcinoma,adenocarcinoma3
26729850EGFRlung,NS,carcinoma,adenocarcinoma3
26813979EGFRlung,NS,carcinoma,adenocarcinoma3
26913431EGFRlung,NS,carcinoma,adenocarcinoma3
27020817EGFRlung,NS,carcinoma,adenocarcinoma3
271382935EGFRlung,NS,carcinoma,adenocarcinoma3
27218422EGFRlung,NS,carcinoma,adenocarcinoma3
27320819EGFRlung,NS,carcinoma,adenocarcinoma3
2741716258EGFRlung,NS,carcinoma,adenocarcinoma3
27526445EGFRlung,NS,carcinoma,adenocarcinoma3
2761550028EGFRlung,NS,carcinoma,adenocarcinoma3
27721621EGFRlung,NS,carcinoma,adenocarcinoma3
27829578EGFRlung,NS,carcinoma,adenocarcinoma3
27951497EGFRlung,NS,carcinoma,adenocarcinoma3
28013553EGFRlung,NS,carcinoma,adenocarcinoma3
28152932EGFRlung,NS,carcinoma,adenocarcinoma3
2821716256EGFRlung,NS,carcinoma,adenocarcinoma3
283383489EGFRlung,NS,carcinoma,adenocarcinoma3
28428605EGFRlung,NS,carcinoma,adenocarcinoma3
2851187305EGFRlung,NS,carcinoma,adenocarcinoma3
286214349EGFRlung,NS,carcinoma,adenocarcinoma3
2871235378EGFRlung,NS,carcinoma,adenocarcinoma3
28812675EGFRlung,NS,carcinoma,adenocarcinoma3
28935840EGFRlung,NS,carcinoma,adenocarcinoma3
290375343EGFRlung,NS,carcinoma,adenocarcinoma3
29151496EGFRlung,NS,carcinoma,adenocarcinoma3
29223617EGFRlung,NS,carcinoma,adenocarcinoma3
293133566EGFRlung,NS,carcinoma,adenocarcinoma3
2941667022EGFRlung,NS,carcinoma,adenocarcinoma3
29528486EGFRlung,NS,carcinoma,adenocarcinoma3
296374570EGFRlung,NS,carcinoma,adenocarcinoma3
29713433EGFRlung,NS,carcinoma,adenocarcinoma3
29826437EGFRlung,NS,carcinoma,adenocarcinoma3
29926438EGFRlung,NS,carcinoma,adenocarcinoma3
3006226EGFRlung,NS,carcinoma,adenocarcinoma3
301250050EGFRlung,NS,carcinoma,adenocarcinoma3
30226131EGFRlung,NS,carcinoma,adenocarcinoma3
3031651578EGFRlung,NS,carcinoma,adenocarcinoma3
30427096EGFRlung,NS,carcinoma,adenocarcinoma3
30514068EGFRlung,NS,carcinoma,adenocarcinoma3
3066242EGFRlung,NS,carcinoma,adenocarcinoma3
30728511EGFRlung,NS,carcinoma,adenocarcinoma3
30852934EGFRlung,NS,carcinoma,adenocarcinoma3
30948318EGFRlung,NS,carcinoma,adenocarcinoma3
31028603EGFRlung,NS,carcinoma,adenocarcinoma3
31122943EGFRlung,NS,carcinoma,adenocarcinoma3
3121684685EGFRlung,NS,carcinoma,adenocarcinoma3
313211764EGFRlung,NS,carcinoma,adenocarcinoma3
31413194EGFRlung,NS,carcinoma,adenocarcinoma3
31528508EGFRlung,NS,carcinoma,adenocarcinoma3
316355283EGFRlung,NS,carcinoma,adenocarcinoma3
31794181EGFRlung,NS,carcinoma,adenocarcinoma3
31821943EGFRlung,NS,carcinoma,adenocarcinoma3
31913427EGFRlung,NS,carcinoma,adenocarcinoma3
32013430EGFRlung,NS,carcinoma,adenocarcinoma3
32118486EGFRlung,NS,carcinoma,adenocarcinoma3
32212429EGFRlung,NS,carcinoma,adenocarcinoma3
32318419EGFRlung,NS,carcinoma,adenocarcinoma3
32422940EGFRlung,NS,carcinoma,adenocarcinoma3
3256268EGFRlung,NS,carcinoma,adenocarcinoma3
3266252EGFRlung,NS,carcinoma,adenocarcinoma3
32718423EGFRlung,NS,carcinoma,adenocarcinoma3
32885993EGFRlung,NS,carcinoma,adenocarcinoma3
3296253EGFRlung,NS,carcinoma,adenocarcinoma3
33013447EGFRlung,NS,carcinoma,adenocarcinoma3
33121984EGFRlung,NS,carcinoma,adenocarcinoma3
33220881EGFRlung,NS,carcinoma,adenocarcinoma3
33313173EGFRlung,NS,carcinoma,adenocarcinoma3
33420894EGFRlung,NS,carcinoma,adenocarcinoma3
33527625EGFRlung,NS,carcinoma,adenocarcinoma3
33685992EGFRlung,NS,carcinoma,adenocarcinoma3
3376239EGFRlung,NS,carcinoma,adenocarcinoma3
3386224EGFRlung,NS,carcinoma,adenocarcinoma3
3396240EGFRlung,NS,carcinoma,adenocarcinoma3
3406241EGFRlung,NS,carcinoma,adenocarcinoma3
34128604EGFRlung,NS,carcinoma,adenocarcinoma3
34228609EGFRlung,NS,carcinoma,adenocarcinoma3
34328739EGFRlung,NS,carcinoma,adenocarcinoma3
34413983EGFRlung,NS,carcinoma,adenocarcinoma3
34528610EGFRlung,NS,carcinoma,adenocarcinoma3
34628554EGFRlung,NS,carcinoma,adenocarcinoma3
34753105EGFRlung,NS,carcinoma,adenocarcinoma3
34826411EGFRlung,NS,carcinoma,adenocarcinoma3
34928619EGFRlung,NS,carcinoma,adenocarcinoma3
350370916EGFRlung,NS,carcinoma,adenocarcinoma3
35120847EGFRlung,NS,carcinoma,adenocarcinoma3
35213448EGFRlung,NS,carcinoma,adenocarcinoma3
35313424EGFRlung,NS,carcinoma,adenocarcinoma3
35428516EGFRlung,NS,carcinoma,adenocarcinoma3
35528608EGFRlung,NS,carcinoma,adenocarcinoma3
35685994EGFRlung,NS,carcinoma,adenocarcinoma3
3571667028EGFRlung,NS,carcinoma,adenocarcinoma3
35828514EGFRlung,NS,carcinoma,adenocarcinoma3
35985960EGFRlung,NS,carcinoma,adenocarcinoma3
36022992EGFRlung,NS,carcinoma,adenocarcinoma3
36121390EGFRlung,NS,carcinoma,adenocarcinoma3
36294183EGFRlung,NS,carcinoma,adenocarcinoma3
363219794EGFRlung,NS,carcinoma,adenocarcinoma3
36433725EGFRlung,NS,carcinoma,adenocarcinoma3
36513009EGFRlung,NS,carcinoma,adenocarcinoma3
36626133EGFRlung,NS,carcinoma,adenocarcinoma3
36712764EGFRlung,NS,carcinoma,adenocarcinoma3
36812988EGFRlung,NS,carcinoma,adenocarcinoma3
36921690EGFRlung,NS,carcinoma,adenocarcinoma3
37052933EGFRlung,NS,carcinoma,adenocarcinoma3
37124848EGFRlung,NS,carcinoma,adenocarcinoma3
37226134EGFRlung,NS,carcinoma,adenocarcinoma3
37330755EGFRlung,NS,carcinoma,adenocarcinoma3
3741166937EGFRlung,NS,carcinoma,adenocarcinoma3
37512366EGFRlung,NS,carcinoma,adenocarcinoma3
37626142EGFRlung,NS,carcinoma,adenocarcinoma3
37713426EGFRlung,NS,carcinoma,adenocarcinoma3
37824428EGFRlung,NS,carcinoma,adenocarcinoma3
3791716257EGFRlung,NS,carcinoma,adenocarcinoma3
380133630EGFRlung,NS,carcinoma,adenocarcinoma3
38124429EGFRlung,NS,carcinoma,adenocarcinoma3
38222420EGFRlung,NS,carcinoma,adenocarcinoma3
38325016EGFRlung,NS,carcinoma,adenocarcinoma3
38427111EGFRlung,NS,carcinoma,adenocarcinoma3
3856227EGFRlung,NS,carcinoma,adenocarcinoma3
38612979EGFRlung,NS,carcinoma,adenocarcinoma3
38721603EGFRlung,NS,carcinoma,adenocarcinoma3
38826412EGFRlung,NS,carcinoma,adenocarcinoma3
38913425EGFRlung,NS,carcinoma,adenocarcinoma3
3906213EGFRlung,NS,carcinoma,adenocarcinoma3
39121602EGFRlung,NS,carcinoma,adenocarcinoma3
39226137EGFRlung,NS,carcinoma,adenocarcinoma3
39326136EGFRlung,NS,carcinoma,adenocarcinoma3
394133565EGFRlung,NS,carcinoma,adenocarcinoma3
39521945EGFRlung,NS,carcinoma,adenocarcinoma3
39622423EGFRlung,NS,carcinoma,adenocarcinoma3
39726144EGFRlung,NS,carcinoma,adenocarcinoma3
39818425EGFRlung,NS,carcinoma,adenocarcinoma3
3991666915EGFRlung,NS,carcinoma,adenocarcinoma3
40023613EGFRlung,NS,carcinoma,adenocarcinoma3
40128510EGFRlung,NS,carcinoma,adenocarcinoma3
40212371EGFRlung,NS,carcinoma,adenocarcinoma3
40388729EGFRlung,NS,carcinoma,adenocarcinoma3
40428602EGFRlung,NS,carcinoma,adenocarcinoma3
405362296ANK2lung,NS,carcinoma,adenocarcinoma3
406384450ANK2lung,NS,carcinoma,adenocarcinoma3
407345583ANK2lung,NS,carcinoma,adenocarcinoma3
408345584ANK2lung,NS,carcinoma,adenocarcinoma3
409347278ANK2lung,NS,carcinoma,adenocarcinoma3
410585696ANK2lung,NS,carcinoma,adenocarcinoma3
411585684ANK2lung,NS,carcinoma,adenocarcinoma3
412585400ANK2lung,NS,carcinoma,adenocarcinoma3
413585409ANK2lung,NS,carcinoma,adenocarcinoma3
414585396ANK2lung,NS,carcinoma,adenocarcinoma3
415402497ANK2lung,NS,carcinoma,adenocarcinoma3
416373837ANK2lung,NS,carcinoma,adenocarcinoma3
417585690ANK2lung,NS,carcinoma,adenocarcinoma3
418340681ANK2lung,NS,carcinoma,adenocarcinoma3
419340683ANK2lung,NS,carcinoma,adenocarcinoma3
420585694ANK2lung,NS,carcinoma,adenocarcinoma3
421350952ANK2lung,NS,carcinoma,adenocarcinoma3
422340682ANK2lung,NS,carcinoma,adenocarcinoma3
423387480ANK2lung,NS,carcinoma,adenocarcinoma3
424342722ANK2lung,NS,carcinoma,adenocarcinoma3
425339156ANK2lung,NS,carcinoma,adenocarcinoma3
4261186636ANK2lung,NS,carcinoma,adenocarcinoma3
427387479ANK2lung,NS,carcinoma,adenocarcinoma3
428359946ANK2lung,NS,carcinoma,adenocarcinoma3
429359947ANK2lung,NS,carcinoma,adenocarcinoma3
430585688ANK2lung,NS,carcinoma,adenocarcinoma3
431336206ANK2lung,NS,carcinoma,adenocarcinoma3
432331394ANK2lung,NS,carcinoma,adenocarcinoma3
433331393ANK2lung,NS,carcinoma,adenocarcinoma3
434336751ANK2lung,NS,carcinoma,adenocarcinoma3
435585693ANK2lung,NS,carcinoma,adenocarcinoma3
436585689ANK2lung,NS,carcinoma,adenocarcinoma3
437370132ANK2lung,NS,carcinoma,adenocarcinoma3
438380187ANK2lung,NS,carcinoma,adenocarcinoma3
439585402ANK2lung,NS,carcinoma,adenocarcinoma3
440585678ANK2lung,NS,carcinoma,adenocarcinoma3
441585399ANK2lung,NS,carcinoma,adenocarcinoma3
442585697ANK2lung,NS,carcinoma,adenocarcinoma3
443585681ANK2lung,NS,carcinoma,adenocarcinoma3
444585673ANK2lung,NS,carcinoma,adenocarcinoma3
445585394ANK2lung,NS,carcinoma,adenocarcinoma3
446359948ANK2lung,NS,carcinoma,adenocarcinoma3
447585393ANK2lung,NS,carcinoma,adenocarcinoma3
448585695ANK2lung,NS,carcinoma,adenocarcinoma3
449585679ANK2lung,NS,carcinoma,adenocarcinoma3
450585674ANK2lung,NS,carcinoma,adenocarcinoma3
4511671222ANK2lung,NS,carcinoma,adenocarcinoma3
452379961ANK2lung,NS,carcinoma,adenocarcinoma3
453377942ANK2lung,NS,carcinoma,adenocarcinoma3
454378503BRAFlung,NS,carcinoma,adenocarcinoma3
45527911BRAFlung,NS,carcinoma,adenocarcinoma3
456364756BRAFlung,NS,carcinoma,adenocarcinoma3
457364757BRAFlung,NS,carcinoma,adenocarcinoma3
458144576BRAFlung,NS,carcinoma,adenocarcinoma3
4596265BRAFlung,NS,carcinoma,adenocarcinoma3
460599331BRAFlung,NS,carcinoma,adenocarcinoma3
46127639BRAFlung,NS,carcinoma,adenocarcinoma3
462446BRAFlung,NS,carcinoma,adenocarcinoma3
463452BRAFlung,NS,carcinoma,adenocarcinoma3
464365398BRAFlung,NS,carcinoma,adenocarcinoma3
46533808BRAFlung,NS,carcinoma,adenocarcinoma3
466957498BRAFlung,NS,carcinoma,adenocarcinoma3
467144978BRAFlung,NS,carcinoma,adenocarcinoma3
46848260BRAFlung,NS,carcinoma,adenocarcinoma3
46913982BRAFlung,NS,carcinoma,adenocarcinoma3
470371552BRAFlung,NS,carcinoma,adenocarcinoma3
471453BRAFlung,NS,carcinoma,adenocarcinoma3
4721133046BRAFlung,NS,carcinoma,adenocarcinoma3
47327330BRAFlung,NS,carcinoma,adenocarcinoma3
474341473BRAFlung,NS,carcinoma,adenocarcinoma3
475471BRAFlung,NS,carcinoma,adenocarcinoma3
4761548506BRAFlung,NS,carcinoma,adenocarcinoma3
47727329BRAFlung,NS,carcinoma,adenocarcinoma3
47829611BRAFlung,NS,carcinoma,adenocarcinoma3
479459BRAFlung,NS,carcinoma,adenocarcinoma3
48029610BRAFlung,NS,carcinoma,adenocarcinoma3
481467BRAFlung,NS,carcinoma,adenocarcinoma3
482460BRAFlung,NS,carcinoma,adenocarcinoma3
483476BRAFlung,NS,carcinoma,adenocarcinoma3
484462BRAFlung,NS,carcinoma,adenocarcinoma3
485451BRAFlung,NS,carcinoma,adenocarcinoma3
4861717456BRAFlung,NS,carcinoma,adenocarcinoma3
4871131BRAFlung,NS,carcinoma,adenocarcinoma3
488470BRAFlung,NS,carcinoma,adenocarcinoma3
48923160BRAFlung,NS,carcinoma,adenocarcinoma3
490478BRAFlung,NS,carcinoma,adenocarcinoma3
4911125BRAFlung,NS,carcinoma,adenocarcinoma3
49229608BRAFlung,NS,carcinoma,adenocarcinoma3
493144979BRAFlung,NS,carcinoma,adenocarcinoma3
494468BRAFlung,NS,carcinoma,adenocarcinoma3
495444BRAFlung,NS,carcinoma,adenocarcinoma3
496599337BRAFlung,NS,carcinoma,adenocarcinoma3
49748261BRAFlung,NS,carcinoma,adenocarcinoma3
498541KRASlung,NS,carcinoma,adenocarcinoma3
49925880KRASlung,NS,carcinoma,adenocarcinoma3
5001169551KRASlung,NS,carcinoma,adenocarcinoma3
501511KRASlung,NS,carcinoma,adenocarcinoma3
50226679KRASlung,NS,carcinoma,adenocarcinoma3
503549KRASlung,NS,carcinoma,adenocarcinoma3
504510KRASlung,NS,carcinoma,adenocarcinoma3
505552KRASlung,NS,carcinoma,adenocarcinoma3
50612721KRASlung,NS,carcinoma,adenocarcinoma3
507542KRASlung,NS,carcinoma,adenocarcinoma3
508515KRASlung,NS,carcinoma,adenocarcinoma3
50912722KRASlung,NS,carcinoma,adenocarcinoma3
51019905KRASlung,NS,carcinoma,adenocarcinoma3
511534KRASlung,NS,carcinoma,adenocarcinoma3
512513KRASlung,NS,carcinoma,adenocarcinoma3
513529KRASlung,NS,carcinoma,adenocarcinoma3
514527KRASlung,NS,carcinoma,adenocarcinoma3
515517KRASlung,NS,carcinoma,adenocarcinoma3
516532KRASlung,NS,carcinoma,adenocarcinoma3
517553KRASlung,NS,carcinoma,adenocarcinoma3
518518KRASlung,NS,carcinoma,adenocarcinoma3
519554KRASlung,NS,carcinoma,adenocarcinoma3
520533KRASlung,NS,carcinoma,adenocarcinoma3
52114201KRASlung,NS,carcinoma,adenocarcinoma3
5221716362KRASlung,NS,carcinoma,adenocarcinoma3
523555KRASlung,NS,carcinoma,adenocarcinoma3
524528KRASlung,NS,carcinoma,adenocarcinoma3
525520KRASlung,NS,carcinoma,adenocarcinoma3
526522KRASlung,NS,carcinoma,adenocarcinoma3
527521KRASlung,NS,carcinoma,adenocarcinoma3
528516KRASlung,NS,carcinoma,adenocarcinoma3
5291537054PIK3CAlung,NS,carcinoma,adenocarcinoma3
53012580PIK3CAlung,NS,carcinoma,adenocarcinoma3
53127502PIK3CAlung,NS,carcinoma,adenocarcinoma3
532776PIK3CAlung,NS,carcinoma,adenocarcinoma3
533582511PIK3CAlung,NS,carcinoma,adenocarcinoma3
53429313PIK3CAlung,NS,carcinoma,adenocarcinoma3
535341932PIK3CAlung,NS,carcinoma,adenocarcinoma3
536760PIK3CAlung,NS,carcinoma,adenocarcinoma3
53748669PIK3CAlung,NS,carcinoma,adenocarcinoma3
538397233PIK3CAlung,NS,carcinoma,adenocarcinoma3
539253279PIK3CAlung,NS,carcinoma,adenocarcinoma3
5401142248PIK3CAlung,NS,carcinoma,adenocarcinoma3
54127497PIK3CAlung,NS,carcinoma,adenocarcinoma3
542582513PIK3CAlung,NS,carcinoma,adenocarcinoma3
543766PIK3CAlung,NS,carcinoma,adenocarcinoma3
5441186459PIK3CAlung,NS,carcinoma,adenocarcinoma3
54529329PIK3CAlung,NS,carcinoma,adenocarcinoma3
54629328PIK3CAlung,NS,carcinoma,adenocarcinoma3
547582520PIK3CAlung,NS,carcinoma,adenocarcinoma3
548219060PIK3CAlung,NS,carcinoma,adenocarcinoma3
54930744PIK3CAlung,NS,carcinoma,adenocarcinoma3
55029325PIK3CAlung,NS,carcinoma,adenocarcinoma3
551219810PIK3CAlung,NS,carcinoma,adenocarcinoma3
552775PIK3CAlung,NS,carcinoma,adenocarcinoma3
55330745PIK3CAlung,NS,carcinoma,adenocarcinoma3
55430739PIK3CAlung,NS,carcinoma,adenocarcinoma3
55585759PIK3CAlung,NS,carcinoma,adenocarcinoma3
55617443PIK3CAlung,NS,carcinoma,adenocarcinoma3
55730743PIK3CAlung,NS,carcinoma,adenocarcinoma3
558759PIK3CAlung,NS,carcinoma,adenocarcinoma3
559763PIK3CAlung,NS,carcinoma,adenocarcinoma3
560598219PIK3CGlung,NS,carcinoma,adenocarcinoma3
56194994PIK3CGlung,NS,carcinoma,adenocarcinoma3
562374594PIK3CGlung,NS,carcinoma,adenocarcinoma3
563357065PIK3CGlung,NS,carcinoma,adenocarcinoma3
56448674PIK3CGlung,NS,carcinoma,adenocarcinoma3
565375344PIK3CGlung,NS,carcinoma,adenocarcinoma3
566342559PIK3CGlung,NS,carcinoma,adenocarcinoma3
567353461PIK3CGlung,NS,carcinoma,adenocarcinoma3
5681547859PIK3CGlung,NS,carcinoma,adenocarcinoma3
56948673PIK3CGlung,NS,carcinoma,adenocarcinoma3
570369193PIK3CGlung,NS,carcinoma,adenocarcinoma3
571598224PIK3CGlung,NS,carcinoma,adenocarcinoma3
572353462PIK3CGlung,NS,carcinoma,adenocarcinoma3
57394993PIK3CGlung,NS,carcinoma,adenocarcinoma3
574598228PIK3CGlung,NS,carcinoma,adenocarcinoma3
575598229PIK3CGlung,NS,carcinoma,adenocarcinoma3
576338828PIK3CGlung,NS,carcinoma,adenocarcinoma3
57794990PIK3CGlung,NS,carcinoma,adenocarcinoma3
578380664PIK3CGlung,NS,carcinoma,adenocarcinoma3
579367472PIK3CGlung,NS,carcinoma,adenocarcinoma3
58048672PIK3CGlung,NS,carcinoma,adenocarcinoma3
58148675PIK3CGlung,NS,carcinoma,adenocarcinoma3
582394825PIK3CGlung,NS,carcinoma,adenocarcinoma3
583598222PIK3CGlung,NS,carcinoma,adenocarcinoma3
584332119PIK3CGlung,NS,carcinoma,adenocarcinoma3
585402921PIK3CGlung,NS,carcinoma,adenocarcinoma3
58694992PIK3CGlung,NS,carcinoma,adenocarcinoma3
587396605PIK3CGlung,NS,carcinoma,adenocarcinoma3
588373298PIK3CGlung,NS,carcinoma,adenocarcinoma3
589372003PIK3CGlung,NS,carcinoma,adenocarcinoma3
590540829ATMlung,NS,carcinoma,adenocarcinoma3
59148246ATMlung,NS,carcinoma,adenocarcinoma3
592540412ATMlung,NS,carcinoma,adenocarcinoma3
593356707ATMlung,NS,carcinoma,adenocarcinoma3
594346969ATMlung,NS,carcinoma,adenocarcinoma3
59548244ATMlung,NS,carcinoma,adenocarcinoma3
596352332ATMlung,NS,carcinoma,adenocarcinoma3
59748247ATMlung,NS,carcinoma,adenocarcinoma3
598385113ATMlung,NS,carcinoma,adenocarcinoma3
599348327ATMlung,NS,carcinoma,adenocarcinoma3
60012950ATMlung,NS,carcinoma,adenocarcinoma3
601540832ATMlung,NS,carcinoma,adenocarcinoma3
602540415ATMlung,NS,carcinoma,adenocarcinoma3
603540827ATMlung,NS,carcinoma,adenocarcinoma3
604333214ATMlung,NS,carcinoma,adenocarcinoma3
60521826ATMlung,NS,carcinoma,adenocarcinoma3
60648242ATMlung,NS,carcinoma,adenocarcinoma3
6071667048ATMlung,NS,carcinoma,adenocarcinoma3
608365639ATMlung,NS,carcinoma,adenocarcinoma3
60921626ATMlung,NS,carcinoma,adenocarcinoma3
610540836ATMlung,NS,carcinoma,adenocarcinoma3
61148241ATMlung,NS,carcinoma,adenocarcinoma3
612332194ATMlung,NS,carcinoma,adenocarcinoma3
613371274ATMlung,NS,carcinoma,adenocarcinoma3
614540823ATMlung,NS,carcinoma,adenocarcinoma3
61548245ATMlung,NS,carcinoma,adenocarcinoma3
61621323ATMlung,NS,carcinoma,adenocarcinoma3
61712951ATMlung,NS,carcinoma,adenocarcinoma3
618540828ATMlung,NS,carcinoma,adenocarcinoma3
61951520STK11lung,NS,carcinoma,adenocarcinoma3
620564708STK11lung,NS,carcinoma,adenocarcinoma3
62125849STK11lung,NS,carcinoma,adenocarcinoma3
62225847STK11lung,NS,carcinoma,adenocarcinoma3
623400197STK11lung,NS,carcinoma,adenocarcinoma3
624564713STK11lung,NS,carcinoma,adenocarcinoma3
625564714STK11lung,NS,carcinoma,adenocarcinoma3
6261189750STK11lung,NS,carcinoma,adenocarcinoma3
62727312STK11lung,NS,carcinoma,adenocarcinoma3
62848785STK11lung,NS,carcinoma,adenocarcinoma3
62948786STK11lung,NS,carcinoma,adenocarcinoma3
63027314STK11lung,NS,carcinoma,adenocarcinoma3
63196528STK11lung,NS,carcinoma,adenocarcinoma3
63248787STK11lung,NS,carcinoma,adenocarcinoma3
63396527STK11lung,NS,carcinoma,adenocarcinoma3
63448788STK11lung,NS,carcinoma,adenocarcinoma3
635564710STK11lung,NS,carcinoma,adenocarcinoma3
63625844STK11lung,NS,carcinoma,adenocarcinoma3
637377895STK11lung,NS,carcinoma,adenocarcinoma3
638333593STK11lung,NS,carcinoma,adenocarcinoma3
63927283STK11lung,NS,carcinoma,adenocarcinoma3
64020944STK11lung,NS,carcinoma,adenocarcinoma3
641564715STK11lung,NS,carcinoma,adenocarcinoma3
642564707STK11lung,NS,carcinoma,adenocarcinoma3
64348783STK11lung,NS,carcinoma,adenocarcinoma3
64448789STK11lung,NS,carcinoma,adenocarcinoma3
64520957STK11lung,NS,carcinoma,adenocarcinoma3
646564712STK11lung,NS,carcinoma,adenocarcinoma3
647363345ERBB4lung,NS,carcinoma,adenocarcinoma3
648354281ERBB4lung,NS,carcinoma,adenocarcinoma3
649400589ERBB4lung,NS,carcinoma,adenocarcinoma3
650573366ERBB4lung,NS,carcinoma,adenocarcinoma3
651392974ERBB4lung,NS,carcinoma,adenocarcinoma3
652378328ERBB4lung,NS,carcinoma,adenocarcinoma3
653573365ERBB4lung,NS,carcinoma,adenocarcinoma3
654573355ERBB4lung,NS,carcinoma,adenocarcinoma3
655353100ERBB4lung,NS,carcinoma,adenocarcinoma3
656573428ERBB4lung,NS,carcinoma,adenocarcinoma3
657341298ERBB4lung,NS,carcinoma,adenocarcinoma3
658573415ERBB4lung,NS,carcinoma,adenocarcinoma3
65948363ERBB4lung,NS,carcinoma,adenocarcinoma3
660573360ERBB4lung,NS,carcinoma,adenocarcinoma3
661334437ERBB4lung,NS,carcinoma,adenocarcinoma3
66248364ERBB4lung,NS,carcinoma,adenocarcinoma3
663399094ERBB4lung,NS,carcinoma,adenocarcinoma3
66448368ERBB4lung,NS,carcinoma,adenocarcinoma3
66548367ERBB4lung,NS,carcinoma,adenocarcinoma3
666338297ERBB4lung,NS,carcinoma,adenocarcinoma3
66748366ERBB4lung,NS,carcinoma,adenocarcinoma3
668573362ERBB4lung,NS,carcinoma,adenocarcinoma3
669352121ERBB4lung,NS,carcinoma,adenocarcinoma3
670573353ERBB4lung,NS,carcinoma,adenocarcinoma3
671394749ERBB4lung,NS,carcinoma,adenocarcinoma3
67248361ERBB4lung,NS,carcinoma,adenocarcinoma3
67348362ERBB4lung,NS,carcinoma,adenocarcinoma3
674354874ERBB4lung,NS,carcinoma,adenocarcinoma3
675608445CDKN2Alung,NS,carcinoma,adenocarcinoma3
67613615CDKN2Alung,NS,carcinoma,adenocarcinoma3
67713488CDKN2Alung,NS,carcinoma,adenocarcinoma3
678342060CDKN2Alung,NS,carcinoma,adenocarcinoma3
67913617CDKN2Alung,NS,carcinoma,adenocarcinoma3
68013614CDKN2Alung,NS,carcinoma,adenocarcinoma3
68148300CDKN2Alung,NS,carcinoma,adenocarcinoma3
68248297CDKN2Alung,NS,carcinoma,adenocarcinoma3
683608437CDKN2Alung,NS,carcinoma,adenocarcinoma3
68413820CDKN2Alung,NS,carcinoma,adenocarcinoma3
68513296CDKN2Alung,NS,carcinoma,adenocarcinoma3
68613299CDKN2Alung,NS,carcinoma,adenocarcinoma3
68713298CDKN2Alung,NS,carcinoma,adenocarcinoma3
68813280CDKN2Alung,NS,carcinoma,adenocarcinoma3
68913618CDKN2Alung,NS,carcinoma,adenocarcinoma3
69013612CDKN2Alung,NS,carcinoma,adenocarcinoma3
69113613CDKN2Alung,NS,carcinoma,adenocarcinoma3
69248299CDKN2Alung,NS,carcinoma,adenocarcinoma3
69312504CDKN2Alung,NS,carcinoma,adenocarcinoma3
69413295CDKN2Alung,NS,carcinoma,adenocarcinoma3
69512509CDKN2Alung,NS,carcinoma,adenocarcinoma3
69612746CDKN2Alung,NS,carcinoma,adenocarcinoma3
69748298CDKN2Alung,NS,carcinoma,adenocarcinoma3
69813616CDKN2Alung,NS,carcinoma,adenocarcinoma3
69913294CDKN2Alung,NS,carcinoma,adenocarcinoma3
70013604CDKN2Alung,NS,carcinoma,adenocarcinoma3
701547456PIK3C2Glung,NS,carcinoma,adenocarcinoma3
70248661PIK3C2Glung,NS,carcinoma,adenocarcinoma3
703340053PIK3C2Glung,NS,carcinoma,adenocarcinoma3
70448662PIK3C2Glung,NS,carcinoma,adenocarcinoma3
705374094PIK3C2Glung,NS,carcinoma,adenocarcinoma3
706381878PIK3C2Glung,NS,carcinoma,adenocarcinoma3
707348619PIK3C2Glung,NS,carcinoma,adenocarcinoma3
70848660PIK3C2Glung,NS,carcinoma,adenocarcinoma3
709547462PIK3C2Glung,NS,carcinoma,adenocarcinoma3
710386507PIK3C2Glung,NS,carcinoma,adenocarcinoma3
711344133PIK3C2Glung,NS,carcinoma,adenocarcinoma3
712401325PIK3C2Glung,NS,carcinoma,adenocarcinoma3
71394973PIK3C2Glung,NS,carcinoma,adenocarcinoma3
71448659PIK3C2Glung,NS,carcinoma,adenocarcinoma3
715369848PIK3C2Glung,NS,carcinoma,adenocarcinoma3
716547454PIK3C2Glung,NS,carcinoma,adenocarcinoma3
717363678PIK3C2Glung,NS,carcinoma,adenocarcinoma3
71894976PIK3C2Glung,NS,carcinoma,adenocarcinoma3
719401323PIK3C2Glung,NS,carcinoma,adenocarcinoma3
720381351PIK3C2Glung,NS,carcinoma,adenocarcinoma3
721389038PIK3C2Glung,NS,carcinoma,adenocarcinoma3
722372700PIK3C2Glung,NS,carcinoma,adenocarcinoma3
723547450PIK3C2Glung,NS,carcinoma,adenocarcinoma3
724363379EPHA5lung,NS,carcinoma,adenocarcinoma3
725588057EPHA5lung,NS,carcinoma,adenocarcinoma3
726364624EPHA5lung,NS,carcinoma,adenocarcinoma3
727381009EPHA5lung,NS,carcinoma,adenocarcinoma3
728387446EPHA5lung,NS,carcinoma,adenocarcinoma3
729387447EPHA5lung,NS,carcinoma,adenocarcinoma3
730588045EPHA5lung,NS,carcinoma,adenocarcinoma3
731588062EPHA5lung,NS,carcinoma,adenocarcinoma3
732390223EPHA5lung,NS,carcinoma,adenocarcinoma3
733588046EPHA5lung,NS,carcinoma,adenocarcinoma3
734588065EPHA5lung,NS,carcinoma,adenocarcinoma3
735332042EPHA5lung,NS,carcinoma,adenocarcinoma3
73694202EPHA5lung,NS,carcinoma,adenocarcinoma3
737588061EPHA5lung,NS,carcinoma,adenocarcinoma3
73848336EPHA5lung,NS,carcinoma,adenocarcinoma3
739397805EPHA5lung,NS,carcinoma,adenocarcinoma3
74048333EPHA5lung,NS,carcinoma,adenocarcinoma3
74148337EPHA5lung,NS,carcinoma,adenocarcinoma3
742588059EPHA5lung,NS,carcinoma,adenocarcinoma3
743334597EPHA5lung,NS,carcinoma,adenocarcinoma3
744588064EPHA5lung,NS,carcinoma,adenocarcinoma3
745588058EPHA5lung,NS,carcinoma,adenocarcinoma3
746588066EPHA5lung,NS,carcinoma,adenocarcinoma3
747387933TRPS1lung,NS,carcinoma,adenocarcinoma3
748374657TRPS1lung,NS,carcinoma,adenocarcinoma3
749603723TRPS1lung,NS,carcinoma,adenocarcinoma3
750346035TRPS1lung,NS,carcinoma,adenocarcinoma3
751603727TRPS1lung,NS,carcinoma,adenocarcinoma3
752353567TRPS1lung,NS,carcinoma,adenocarcinoma3
753369200TRPS1lung,NS,carcinoma,adenocarcinoma3
754603708TRPS1lung,NS,carcinoma,adenocarcinoma3
755603731TRPS1lung,NS,carcinoma,adenocarcinoma3
756603725TRPS1lung,NS,carcinoma,adenocarcinoma3
757378546TRPS1lung,NS,carcinoma,adenocarcinoma3
758366705TRPS1lung,NS,carcinoma,adenocarcinoma3
759603670TRPS1lung,NS,carcinoma,adenocarcinoma3
760369019TRPS1lung,NS,carcinoma,adenocarcinoma3
761355314TRPS1lung,NS,carcinoma,adenocarcinoma3
762603710TRPS1lung,NS,carcinoma,adenocarcinoma3
763338058TRPS1lung,NS,carcinoma,adenocarcinoma3
764603676TRPS1lung,NS,carcinoma,adenocarcinoma3
765603674TRPS1lung,NS,carcinoma,adenocarcinoma3
766603706TRPS1lung,NS,carcinoma,adenocarcinoma3
767603729TRPS1lung,NS,carcinoma,adenocarcinoma3
768603668TRPS1lung,NS,carcinoma,adenocarcinoma3
769337193ANK1lung,NS,carcinoma,adenocarcinoma3
770605449ANK1lung,NS,carcinoma,adenocarcinoma3
771364780ANK1lung,NS,carcinoma,adenocarcinoma3
772366691ANK1lung,NS,carcinoma,adenocarcinoma3
773605698ANK1lung,NS,carcinoma,adenocarcinoma3
774387891ANK1lung,NS,carcinoma,adenocarcinoma3
775351790ANK1lung,NS,carcinoma,adenocarcinoma3
776351792ANK1lung,NS,carcinoma,adenocarcinoma3
777375128ANK1lung,NS,carcinoma,adenocarcinoma3
778339907ANK1lung,NS,carcinoma,adenocarcinoma3
779360431ANK1lung,NS,carcinoma,adenocarcinoma3
780367497ANK1lung,NS,carcinoma,adenocarcinoma3
781369005ANK1lung,NS,carcinoma,adenocarcinoma3
782331619ANK1lung,NS,carcinoma,adenocarcinoma3
783605446ANK1lung,NS,carcinoma,adenocarcinoma3
784605447ANK1lung,NS,carcinoma,adenocarcinoma3
785338075ANK1lung,NS,carcinoma,adenocarcinoma3
786605450ANK1lung,NS,carcinoma,adenocarcinoma3
787352245ANK1lung,NS,carcinoma,adenocarcinoma3
788605695ANK1lung,NS,carcinoma,adenocarcinoma3
789605694ANK1lung,NS,carcinoma,adenocarcinoma3
79094563KDRlung,NS,carcinoma,adenocarcinoma3
791384448KDRlung,NS,carcinoma,adenocarcinoma3
79294565KDRlung,NS,carcinoma,adenocarcinoma3
79348463KDRlung,NS,carcinoma,adenocarcinoma3
794371151KDRlung,NS,carcinoma,adenocarcinoma3
795345642KDRlung,NS,carcinoma,adenocarcinoma3
7961430203KDRlung,NS,carcinoma,adenocarcinoma3
797587602KDRlung,NS,carcinoma,adenocarcinoma3
79848462KDRlung,NS,carcinoma,adenocarcinoma3
799359912KDRlung,NS,carcinoma,adenocarcinoma3
80094566KDRlung,NS,carcinoma,adenocarcinoma3
80148461KDRlung,NS,carcinoma,adenocarcinoma3
802587596KDRlung,NS,carcinoma,adenocarcinoma3
803587600KDRlung,NS,carcinoma,adenocarcinoma3
804365817KDRlung,NS,carcinoma,adenocarcinoma3
805337898KDRlung,NS,carcinoma,adenocarcinoma3
80648465KDRlung,NS,carcinoma,adenocarcinoma3
80748464KDRlung,NS,carcinoma,adenocarcinoma3
80848460KDRlung,NS,carcinoma,adenocarcinoma3
809587599KDRlung,NS,carcinoma,adenocarcinoma3
810335666PDGFRAlung,NS,carcinoma,adenocarcinoma3
811587618PDGFRAlung,NS,carcinoma,adenocarcinoma3
812365272PDGFRAlung,NS,carcinoma,adenocarcinoma3
813587619PDGFRAlung,NS,carcinoma,adenocarcinoma3
81494953PDGFRAlung,NS,carcinoma,adenocarcinoma3
815382331PDGFRAlung,NS,carcinoma,adenocarcinoma3
81648646PDGFRAlung,NS,carcinoma,adenocarcinoma3
817587614PDGFRAlung,NS,carcinoma,adenocarcinoma3
81848647PDGFRAlung,NS,carcinoma,adenocarcinoma3
819345640PDGFRAlung,NS,carcinoma,adenocarcinoma3
820378406PDGFRAlung,NS,carcinoma,adenocarcinoma3
821587608PDGFRAlung,NS,carcinoma,adenocarcinoma3
822380580PDGFRAlung,NS,carcinoma,adenocarcinoma3
823365816PDGFRAlung,NS,carcinoma,adenocarcinoma3
82494949PDGFRAlung,NS,carcinoma,adenocarcinoma3
82594951PDGFRAlung,NS,carcinoma,adenocarcinoma3
826587617PDGFRAlung,NS,carcinoma,adenocarcinoma3
82748644PDGFRAlung,NS,carcinoma,adenocarcinoma3
828402444PDGFRAlung,NS,carcinoma,adenocarcinoma3
829355205PDGFRAlung,NS,carcinoma,adenocarcinoma3
830578598TPTElung,NS,carcinoma,adenocarcinoma3
831578872TPTElung,NS,carcinoma,adenocarcinoma3
832357325TPTElung,NS,carcinoma,adenocarcinoma3
833342964TPTElung,NS,carcinoma,adenocarcinoma3
834375058TPTElung,NS,carcinoma,adenocarcinoma3
8351194919TPTElung,NS,carcinoma,adenocarcinoma3
836335136TPTElung,NS,carcinoma,adenocarcinoma3
83748822TPTElung,NS,carcinoma,adenocarcinoma3
838395189TPTElung,NS,carcinoma,adenocarcinoma3
839578594TPTElung,NS,carcinoma,adenocarcinoma3
840339759TPTElung,NS,carcinoma,adenocarcinoma3
841371861TPTElung,NS,carcinoma,adenocarcinoma3
842397668TPTElung,NS,carcinoma,adenocarcinoma3
843578595TPTElung,NS,carcinoma,adenocarcinoma3
844365780TPTElung,NS,carcinoma,adenocarcinoma3
845578881TPTElung,NS,carcinoma,adenocarcinoma3
846578591TPTElung,NS,carcinoma,adenocarcinoma3
847363925TPTElung,NS,carcinoma,adenocarcinoma3
848578882TPTElung,NS,carcinoma,adenocarcinoma3
849394729TPTElung,NS,carcinoma,adenocarcinoma3
850361346UBR4lung,NS,carcinoma,adenocarcinoma3
851393437UBR4lung,NS,carcinoma,adenocarcinoma3
852531411UBR4lung,NS,carcinoma,adenocarcinoma3
853344924UBR4lung,NS,carcinoma,adenocarcinoma3
854373893UBR4lung,NS,carcinoma,adenocarcinoma3
855349909UBR4lung,NS,carcinoma,adenocarcinoma3
856531405UBR4lung,NS,carcinoma,adenocarcinoma3
857531397UBR4lung,NS,carcinoma,adenocarcinoma3
858400767UBR4lung,NS,carcinoma,adenocarcinoma3
859355546UBR4lung,NS,carcinoma,adenocarcinoma3
860331153UBR4lung,NS,carcinoma,adenocarcinoma3
861531412UBR4lung,NS,carcinoma,adenocarcinoma3
862531407UBR4lung,NS,carcinoma,adenocarcinoma3
863531400UBR4lung,NS,carcinoma,adenocarcinoma3
864531402UBR4lung,NS,carcinoma,adenocarcinoma3
865358081UBR4lung,NS,carcinoma,adenocarcinoma3
866531398UBR4lung,NS,carcinoma,adenocarcinoma3
867531413UBR4lung,NS,carcinoma,adenocarcinoma3
868531415UBR4lung,NS,carcinoma,adenocarcinoma3
869361162NTRK3lung,NS,carcinoma,adenocarcinoma3
870386693NTRK3lung,NS,carcinoma,adenocarcinoma3
871556458NTRK3lung,NS,carcinoma,adenocarcinoma3
872556476NTRK3lung,NS,carcinoma,adenocarcinoma3
8731517970NTRK3lung,NS,carcinoma,adenocarcinoma3
874349130NTRK3lung,NS,carcinoma,adenocarcinoma3
875556472NTRK3lung,NS,carcinoma,adenocarcinoma3
876395008NTRK3lung,NS,carcinoma,adenocarcinoma3
877556484NTRK3lung,NS,carcinoma,adenocarcinoma3
878556461NTRK3lung,NS,carcinoma,adenocarcinoma3
879556446NTRK3lung,NS,carcinoma,adenocarcinoma3
88048625NTRK3lung,NS,carcinoma,adenocarcinoma3
881556467NTRK3lung,NS,carcinoma,adenocarcinoma3
88248620NTRK3lung,NS,carcinoma,adenocarcinoma3
883379875NTRK3lung,NS,carcinoma,adenocarcinoma3
884556486NTRK3lung,NS,carcinoma,adenocarcinoma3
88548621NTRK3lung,NS,carcinoma,adenocarcinoma3
886556480NTRK3lung,NS,carcinoma,adenocarcinoma3
887556443NTRK3lung,NS,carcinoma,adenocarcinoma3
888377166NF1lung,NS,carcinoma,adenocarcinoma3
889400527NF1lung,NS,carcinoma,adenocarcinoma3
890393297NF1lung,NS,carcinoma,adenocarcinoma3
891145671NF1lung,NS,carcinoma,adenocarcinoma3
892560371NF1lung,NS,carcinoma,adenocarcinoma3
89348596NF1lung,NS,carcinoma,adenocarcinoma3
894382826NF1lung,NS,carcinoma,adenocarcinoma3
895341094NF1lung,NS,carcinoma,adenocarcinoma3
8961189436NF1lung,NS,carcinoma,adenocarcinoma3
89794824NF1lung,NS,carcinoma,adenocarcinoma3
898560379NF1lung,NS,carcinoma,adenocarcinoma3
899560397NF1lung,NS,carcinoma,adenocarcinoma3
900332289NF1lung,NS,carcinoma,adenocarcinoma3
901560395NF1lung,NS,carcinoma,adenocarcinoma3
902400351NF1lung,NS,carcinoma,adenocarcinoma3
90348595NF1lung,NS,carcinoma,adenocarcinoma3
904401697NF1lung,NS,carcinoma,adenocarcinoma3
905560401NF1lung,NS,carcinoma,adenocarcinoma3
906374365LRP1Blung,NS,carcinoma,adenocarcinoma3
907570104LRP1Blung,NS,carcinoma,adenocarcinoma3
90848503LRP1Blung,NS,carcinoma,adenocarcinoma3
909383278LRP1Blung,NS,carcinoma,adenocarcinoma3
910570134LRP1Blung,NS,carcinoma,adenocarcinoma3
911570091LRP1Blung,NS,carcinoma,adenocarcinoma3
912347456LRP1Blung,NS,carcinoma,adenocarcinoma3
913353023LRP1Blung,NS,carcinoma,adenocarcinoma3
914362774LRP1Blung,NS,carcinoma,adenocarcinoma3
915570082LRP1Blung,NS,carcinoma,adenocarcinoma3
91648505LRP1Blung,NS,carcinoma,adenocarcinoma3
917363882LRP1Blung,NS,carcinoma,adenocarcinoma3
918570170LRP1Blung,NS,carcinoma,adenocarcinoma3
919570162LRP1Blung,NS,carcinoma,adenocarcinoma3
920359544LRP1Blung,NS,carcinoma,adenocarcinoma3
921402014LRP1Blung,NS,carcinoma,adenocarcinoma3
922331963LRP1Blung,NS,carcinoma,adenocarcinoma3
923370021LRP1Blung,NS,carcinoma,adenocarcinoma3
924335752RUNX1T1lung,NS,carcinoma,adenocarcinoma3
925342047RUNX1T1lung,NS,carcinoma,adenocarcinoma3
926334883RUNX1T1lung,NS,carcinoma,adenocarcinoma3
92795220RUNX1T1lung,NS,carcinoma,adenocarcinoma3
928606465RUNX1T1lung,NS,carcinoma,adenocarcinoma3
929606478RUNX1T1lung,NS,carcinoma,adenocarcinoma3
930351831RUNX1T1lung,NS,carcinoma,adenocarcinoma3
931606456RUNX1T1lung,NS,carcinoma,adenocarcinoma3
932606487RUNX1T1lung,NS,carcinoma,adenocarcinoma3
933394583RUNX1T1lung,NS,carcinoma,adenocarcinoma3
934606453RUNX1T1lung,NS,carcinoma,adenocarcinoma3
935331637RUNX1T1lung,NS,carcinoma,adenocarcinoma3
936606474RUNX1T1lung,NS,carcinoma,adenocarcinoma3
937377746RUNX1T1lung,NS,carcinoma,adenocarcinoma3
938380685RUNX1T1lung,NS,carcinoma,adenocarcinoma3
939338096RUNX1T1lung,NS,carcinoma,adenocarcinoma3
940377749RUNX1T1lung,NS,carcinoma,adenocarcinoma3
941606490RUNX1T1lung,NS,carcinoma,adenocarcinoma3
942373941ASTN1lung,NS,carcinoma,adenocarcinoma3
943343546ASTN1lung,NS,carcinoma,adenocarcinoma3
944363168ASTN1lung,NS,carcinoma,adenocarcinoma3
945530674ASTN1lung,NS,carcinoma,adenocarcinoma3
946370367ASTN1lung,NS,carcinoma,adenocarcinoma3
947335099ASTN1lung,NS,carcinoma,adenocarcinoma3
948530668ASTN1lung,NS,carcinoma,adenocarcinoma3
949365986ASTN1lung,NS,carcinoma,adenocarcinoma3
950400907ASTN1lung,NS,carcinoma,adenocarcinoma3
951137330ASTN1lung,NS,carcinoma,adenocarcinoma3
952530672ASTN1lung,NS,carcinoma,adenocarcinoma3
953530673ASTN1lung,NS,carcinoma,adenocarcinoma3
954337627ASTN1lung,NS,carcinoma,adenocarcinoma3
955336619ASTN1lung,NS,carcinoma,adenocarcinoma3
956371231ASTN1lung,NS,carcinoma,adenocarcinoma3
957398524ASTN1lung,NS,carcinoma,adenocarcinoma3
958530675ASTN1lung,NS,carcinoma,adenocarcinoma3
9595661CTNNB1lung,NS,carcinoma,adenocarcinoma3
960583550CTNNB1lung,NS,carcinoma,adenocarcinoma3
9615670CTNNB1lung,NS,carcinoma,adenocarcinoma3
9625677CTNNB1lung,NS,carcinoma,adenocarcinoma3
9635679CTNNB1lung,NS,carcinoma,adenocarcinoma3
9645663CTNNB1lung,NS,carcinoma,adenocarcinoma3
965583555CTNNB1lung,NS,carcinoma,adenocarcinoma3
9665686CTNNB1lung,NS,carcinoma,adenocarcinoma3
9675740CTNNB1lung,NS,carcinoma,adenocarcinoma3
96894106CTNNB1lung,NS,carcinoma,adenocarcinoma3
969396036CTNNB1lung,NS,carcinoma,adenocarcinoma3
9705681CTNNB1lung,NS,carcinoma,adenocarcinoma3
9715671CTNNB1lung,NS,carcinoma,adenocarcinoma3
97229398CTNNB1lung,NS,carcinoma,adenocarcinoma3
9735662CTNNB1lung,NS,carcinoma,adenocarcinoma3
9745664CTNNB1lung,NS,carcinoma,adenocarcinoma3
975342959PTPRTlung,NS,carcinoma,adenocarcinoma3
976402209PTPRTlung,NS,carcinoma,adenocarcinoma3
977378746PTPRTlung,NS,carcinoma,adenocarcinoma3
978384406PTPRTlung,NS,carcinoma,adenocarcinoma3
979335565PTPRTlung,NS,carcinoma,adenocarcinoma3
980341226PTPRTlung,NS,carcinoma,adenocarcinoma3
981577759PTPRTlung,NS,carcinoma,adenocarcinoma3
982577760PTPRTlung,NS,carcinoma,adenocarcinoma3
983359689PTPRTlung,NS,carcinoma,adenocarcinoma3
984577362PTPRTlung,NS,carcinoma,adenocarcinoma3
985577363PTPRTlung,NS,carcinoma,adenocarcinoma3
986337685PTPRTlung,NS,carcinoma,adenocarcinoma3
987334328PTPRTlung,NS,carcinoma,adenocarcinoma3
988359690PTPRTlung,NS,carcinoma,adenocarcinoma3
989359691PTPRTlung,NS,carcinoma,adenocarcinoma3
990577361PTPRTlung,NS,carcinoma,adenocarcinoma3
9911676741GRIN2Blung,NS,carcinoma,adenocarcinoma3
9921676740GRIN2Blung,NS,carcinoma,adenocarcinoma3
993547241GRIN2Blung,NS,carcinoma,adenocarcinoma3
994394098GRIN2Blung,NS,carcinoma,adenocarcinoma3
995386503GRIN2Blung,NS,carcinoma,adenocarcinoma3
996394956GRIN2Blung,NS,carcinoma,adenocarcinoma3
997547239GRIN2Blung,NS,carcinoma,adenocarcinoma3
998343446GRIN2Blung,NS,carcinoma,adenocarcinoma3
999547240GRIN2Blung,NS,carcinoma,adenocarcinoma3
1000547242GRIN2Blung,NS,carcinoma,adenocarcinoma3
1001547238GRIN2Blung,NS,carcinoma,adenocarcinoma3
1002317431GRIN2Blung,NS,carcinoma,adenocarcinoma3
1003358661GRIN2Blung,NS,carcinoma,adenocarcinoma3
1004401318GRIN2Blung,NS,carcinoma,adenocarcinoma3
1005401319GRIN2Blung,NS,carcinoma,adenocarcinoma3
1006547243GRIN2Blung,NS,carcinoma,adenocarcinoma3
10071671545CDH10lung,NS,carcinoma,adenocarcinoma3
1008591859CDH10lung,NS,carcinoma,adenocarcinoma3
1009354480CDH10lung,NS,carcinoma,adenocarcinoma3
1010591856CDH10lung,NS,carcinoma,adenocarcinoma3
1011383413CDH10lung,NS,carcinoma,adenocarcinoma3
10121543389CDH10lung,NS,carcinoma,adenocarcinoma3
1013387531CDH10lung,NS,carcinoma,adenocarcinoma3
1014591857CDH10lung,NS,carcinoma,adenocarcinoma3
1015384459CDH10lung,NS,carcinoma,adenocarcinoma3
1016357764CDH10lung,NS,carcinoma,adenocarcinoma3
1017334645CDH10lung,NS,carcinoma,adenocarcinoma3
1018396588CDH10lung,NS,carcinoma,adenocarcinoma3
1019591853CDH10lung,NS,carcinoma,adenocarcinoma3
1020591858CDH10lung,NS,carcinoma,adenocarcinoma3
1021591861CDH10lung,NS,carcinoma,adenocarcinoma3
1022591862CDH10lung,NS,carcinoma,adenocarcinoma3
1023346726EPHA6lung,NS,carcinoma,adenocarcinoma3
1024340216EPHA6lung,NS,carcinoma,adenocarcinoma3
1025585150EPHA6lung,NS,carcinoma,adenocarcinoma3
102648339EPHA6lung,NS,carcinoma,adenocarcinoma3
1027372244EPHA6lung,NS,carcinoma,adenocarcinoma3
1028585138EPHA6lung,NS,carcinoma,adenocarcinoma3
1029362204EPHA6lung,NS,carcinoma,adenocarcinoma3
1030332931EPHA6lung,NS,carcinoma,adenocarcinoma3
1031331388EPHA6lung,NS,carcinoma,adenocarcinoma3
1032585178EPHA6lung,NS,carcinoma,adenocarcinoma3
1033585142EPHA6lung,NS,carcinoma,adenocarcinoma3
1034585140EPHA6lung,NS,carcinoma,adenocarcinoma3
1035343037EPHA6lung,NS,carcinoma,adenocarcinoma3
1036585136EPHA6lung,NS,carcinoma,adenocarcinoma3
10371197518EPHA6lung,NS,carcinoma,adenocarcinoma3
1038356990EPHA3lung,NS,carcinoma,adenocarcinoma3
1039393636EPHA3lung,NS,carcinoma,adenocarcinoma3
104048330EPHA3lung,NS,carcinoma,adenocarcinoma3
1041384951EPHA3lung,NS,carcinoma,adenocarcinoma3
104248329EPHA3lung,NS,carcinoma,adenocarcinoma3
104348323EPHA3lung,NS,carcinoma,adenocarcinoma3
1044389456EPHA3lung,NS,carcinoma,adenocarcinoma3
1045352149EPHA3lung,NS,carcinoma,adenocarcinoma3
1046370858EPHA3lung,NS,carcinoma,adenocarcinoma3
1047584816EPHA3lung,NS,carcinoma,adenocarcinoma3
104848331EPHA3lung,NS,carcinoma,adenocarcinoma3
1049377628EPHA3lung,NS,carcinoma,adenocarcinoma3
105048322EPHA3lung,NS,carcinoma,adenocarcinoma3
1051584812EPHA3lung,NS,carcinoma,adenocarcinoma3
1052584780EPHA3lung,NS,carcinoma,adenocarcinoma3
105394204EPHA7lung,NS,carcinoma,adenocarcinoma3
1054597715EPHA7lung,NS,carcinoma,adenocarcinoma3
1055360206EPHA7lung,NS,carcinoma,adenocarcinoma3
1056597709EPHA7lung,NS,carcinoma,adenocarcinoma3
1057597702EPHA7lung,NS,carcinoma,adenocarcinoma3
105848340EPHA7lung,NS,carcinoma,adenocarcinoma3
1059597710EPHA7lung,NS,carcinoma,adenocarcinoma3
1060597711EPHA7lung,NS,carcinoma,adenocarcinoma3
1061597707EPHA7lung,NS,carcinoma,adenocarcinoma3
1062597714EPHA7lung,NS,carcinoma,adenocarcinoma3
106348341EPHA7lung,NS,carcinoma,adenocarcinoma3
1064597713EPHA7lung,NS,carcinoma,adenocarcinoma3
106548342EPHA7lung,NS,carcinoma,adenocarcinoma3
1066597703EPHA7lung,NS,carcinoma,adenocarcinoma3
1067597712EPHA7lung,NS,carcinoma,adenocarcinoma3
1068364187TNNI3Klung,NS,carcinoma,adenocarcinoma3
1069536115TNNI3Klung,NS,carcinoma,adenocarcinoma3
1070536111TNNI3Klung,NS,carcinoma,adenocarcinoma3
1071354145TNNI3Klung,NS,carcinoma,adenocarcinoma3
1072536118TNNI3Klung,NS,carcinoma,adenocarcinoma3
1073346597TNNI3Klung,NS,carcinoma,adenocarcinoma3
1074342949TNNI3Klung,NS,carcinoma,adenocarcinoma3
1075400798TNNI3Klung,NS,carcinoma,adenocarcinoma3
1076536116TNNI3Klung,NS,carcinoma,adenocarcinoma3
1077383708TNNI3Klung,NS,carcinoma,adenocarcinoma3
1078536112TNNI3Klung,NS,carcinoma,adenocarcinoma3
1079358148TNNI3Klung,NS,carcinoma,adenocarcinoma3
1080388850TNNI3Klung,NS,carcinoma,adenocarcinoma3
1081536113TNNI3K